

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	1	of	56	Attorney Docket Number	BAYER-0018-A

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	502,504		Thoms	08-01-1893	
	A2	1,792,156		Fitzky	02-10-1931	
	A3	2,046,375		Goldstein et al.	07-07-1936	
	A4	2,093,265		Coffey et al.	09-14-1937	
	A5	2,288,422		Rohm	06-30-1942	
	A6	2,649,476		Martin	08-18-1953	
	A7	2,683,082		Hill et al.	07-06-1954	
	A8	2,722,544		Martin	11-01-1955	
	A9	2,745,874		Schetty et al.	05-15-1956	
	A10	2,781,330		Downey	02-12-1957	
	A11	2,797,214		Bossard	06-25-1957	
	A12	2,867,659		Model et al.	01-06-1959	
	A13	2,877,268		Applegath et al.	03-10-1959	
	A14	2,960,488		Tamblyn et al.	11-15-1960	
	A15	2,973,386		Weldon	02-28-1961	
	A16	3,151,023		Martin	09-29-1964	
	A17	3,200,035		Martin et al.	08-10-1965	
	A18	3,230,141		Frick et al.	01-18-1966	
	A19	3,284,433		Becker et al.	11-08-1966	
	A20	3,424,760		Helsley et al.	01-28-1969	
	A21	3,424,761		Helsley et al.	01-28-1969	
	A22	3,424,762		Helsley	01-28-1969	
	A23	3,547,940		Brantley	12-15-1970	
	A24	3,639,668		Alles et al.	02-01-1972	
	A25	3,646,059		Brantley	02-29-1972	
	A26	3,668,222		Hauser	06-06-1972	
	A27	3,689,550		Schellenbaum et al.	09-05-1972	
	A28	3,743,498		Brantley	07-03-1973	
	A29	3,754,887		Brantley	08-28-1973	
	A30	3,823,161		Lesser	07-09-1974	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	2	of	56	Attorney Docket Number	BAYER-0018-A

U.S. PATENT DOCUMENTS					
		U.S. Patent Document			
	A31	3,828,001		Broad et al.	08-06-1974
	A32	3,860,645		Nikawitz	01-14-1975
	A33	3,990,879		Soper	11-09-1976
	A34	4,001,256		Callahan et al.	01-04-1977
	A35	4,009,847		Aldrich et al.	03-01-1977
	A36	4,042,372		Harper	08-16-1977
	A37	4,062,861		Yukinaga et al.	12-13-1977
	A37a	4,063,928		Johnston	12-20-1977
	A38	4,071,524		Banitt	01-31-1978
	A39	4,103,022		Sirrenberg et al.	07-25-1978
	A40	4,111,680		Yukinaga et al.	09-05-1978
	A41	4,111,683		Singer	09-05-1978
	A42	4,116,671		Yukinaga et al.	09-26-1978
	A43	4,173,637		Nishiyama et al.	11-06-1979
	A44	4,173,638		Nishiyama et al.	11-06-1979
	A45	4,183,854		Crossley	01-15-1980
	A46	4,212,981		Yukinaga et al.	07-15-1980
	A47	4,240,820		Dickore et al.	12-23-1980
	A48	4,279,639		Okamoto et al.	07-21-1981
	A48a	4,293,328		Yukinaga et al.	10-06-1981
	A49	4,358,596		Krüger	11-09-1982
	A50	4,405,644		Kabbe et al.	09-20-1983
	A51	4,410,697		Török et al.	10-18-1983
	A52	4,437,878		Acker et al.	03-20-1984
	A53	4,468,380		O'Doherty et al.	08-28-1984
	A54	4,473,579		Devries et al.	09-25-1984
	A55	4,499,097		Tomcufcik et al.	02-12-1985
	A56	4,511,571		Böger et al.	04-16-1985
	A57	4,514,571		Nakai et al.	04-30-1985
	A58	4,526,997		O'Doherty et al.	07-02-1985
	A59	4,540,566		Davis et al.	09-10-1985
	A60	4,546,191		Nishiyama et al.	10-08-1985

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 3 of 56

U.S. PATENT DOCUMENTS

	U.S. Patent Document			
A61	4,587,240		Hider et al.	05-06-1986
A62	4,623,662		DeVries	11-18-1986
A63	4,643,849		Hirai et al.	02-17-1987
A64	4,740,520		Hallenbach et al.	04-26-1988
A65	4,760,063		Hallenbach et al.	07-26-1988
A66	4,775,763		Dalton et al.	10-04-1988
A67	4,808,588		King	02-28-1989
A68	4,820,871		Kissener et al.	04-11-1989
A69	4,863,924		Haga et al.	09-05-1989
A69a	4,921,525		Grossman et al.	05-01-1990
A70	4,973,675		Israel et al.	11-27-1990
A70a	4,977,169		Häusermann et al.	12-11-1990
A71	4,983,605		Kondo et al.	01-08-1991
A72	4,985,449		Haga et al.	01-15-1991
A72a	4,996,325		Kristinsson	02-26-1991
A73	5,036,072		Nakajima et al.	07-30-1991
A74	5,059,614		Lepage et al.	10-22-1991
A75	5,063,247		Sekiya et al.	11-05-1991
A76	5,098,907	A	Kondo et al.	03-24-1992
A77	5,100,883	A	Schiehser	03-31-1992
A78	5,118,677	A	Caufield	06-02-1992
A79	5,118,678	A	Kao et al.	06-02-1992
A80	5,120,842	A	Failli et al.	06-09-1992
A81	5,130,331	A	Pascual	07-14-1992
A82	5,151,344	A	Abe et al.	09-29-1992
A83	5,151,413	A	Caufield et al.	09-29-1992
A84	5,162,360	A	Creswell et al.	11-10-1992
A84a	5,177,110	A	Oechslein et al.	01-05-1993
A85	5,185,358	A	Creswell et al.	02-09-1993
A86	5,256,790	A	Nelson	10-26-1993
A87	5,258,389	A	Goulet et al.	11-02-1993
A88	5,270,458	A	Lemischka	12-14-1993

Examiner
Signature

Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	4	of	56	Attorney Docket Number	BAYER-0018-A

U.S. PATENT DOCUMENTS						
		U.S. Patent Document				
	A89	5,283,354	A	Lemischka	02-01-1994	
	A90	5,312,820	A	Ashton et al.	05-17-1994	
	A91	5,319,099	A	Kamata et al.	06-07-1994	
	A92	5,378,725	A	Bonjouklian et al.	01-03-1995	
	A93	5,399,566	A	Katano et al.	03-21-1995	
	A94	5,423,905	A	Fringeli	06-13-1995	
	A95	5,429,918	A	Seto et al.	07-04-1995	
	A96	5,432,468	A	Moriyama et al.	07-11-1995	
	A97	5,441,947	A	Dodge et al.	08-15-1995	
	A98	5,447,957	A	Adams et al.	09-05-1995	
	A99	5,456,920	A	Matoba et al.	10-10-1995	
	A100	5,468,773	A	Dodge et al.	11-21-1995	
	A101	5,470,882	A	Dixon et al.	11-28-1995	
	A102	5,480,906	A	Creemer et al.	01-02-1996	
	A103	5,500,424	A	Nagamine et al.	03-19-1996	
	A104	5,508,288	A	Forbes et al.	04-16-1996	
	A105	5,547,966	A	Atwal et al.	08-20-1996	
	A106	5,559,137	A	Adams et al.	09-24-1996	
	A107	5,596,001	A	Hamanaka	01-21-1997	
	A108	5,597,719	A	Freed et al.	01-28-1997	
	A109	5,624,937	A	Reel et al.	04-29-1997	
	A110	5,656,612	A	Monia	08-12-1997	
	A111	5,658,903	A	Adams et al.	08-19-1997	
	A111a	5,667,226	A	Janich	09-16-1997	
	A112	5,696,138	A	Olesen et al.	12-09-1997	
	A113	5,698,581	A	Kleemann et al.	12-16-1997	
	A114	5,710,094	A	Minami et al.	01-20-1998	
	A115	5,721,237	A	Myers et al.	02-24-1998	
	A116	5,726,167	A	Dodge et al.	03-10-1998	
	A117	5,747,498	A	Schnur et al.	05-05-1998	
	A118	5,773,459	A	Tang et al.	06-30-1998	
	A119	5,777,097	A	Lee et al.	07-07-1998	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	5	of	56	Attorney Docket Number	BAYER-0018-A

U.S. PATENT DOCUMENTS						
		U.S. Patent Document				
	A120	5,780,262	A	Brent et al.	07-14-1998	
	A121	5,780,483	A	Widdowson et al.	07-14-1998	
	A122	5,783,664	A	Lee et al.	07-21-1998	
	A123	5,786,362	A	Krongrad	07-28-1998	
	A123a	5,801,794	A	Lehureau et al.	09-01-1998	
	A124	5,807,876	A	Armistead et al.	09-15-1998	
	A125	5,807,891	A	Bold et al.	09-15-1998	
	A126	5,808,080	A	Bell et al.	09-15-1998	
	A127	5,814,646	A	Heinz et al.	09-29-1998	
	A128	5,869,043	A	McDonnell et al.	02-09-1999	
	A129	5,871,934	A	Lee et al.	02-16-1999	
	A130	5,886,044	A	Widdowson et al.	03-23-1999	
	A131	5,891,895	A	Shiraishi et al.	04-06-1999	
	A132	5,908,865	A	Doi et al.	06-01-1999	
	A133	5,919,773	A	Monia et al.	07-06-1999	
	A134	5,929,250	A	Widdowson et al.	07-27-1999	
	A135	5,955,366	A	Lee et al.	09-21-1999	
	A136	5,965,573	A	Petrie et al.	10-12-1999	
	A137	6,004,965	A	Breu et al.	12-21-1999	
	A138	6,005,008	A	Widdowson et al.	12-21-1999	
	A139	6,015,908	A	Widdowson et al.	01-18-2000	
	A140	6,017,692	A	Brent et al.	01-25-2000	
	A141	6,020,345	A	Vacher et al.	02-01-2000	
	A142	6,022,884	A	Mantlo et al.	02-08-2000	
	A143	6,025,151	A	Peterson	02-15-2000	
	A144	6,033,873	A	McDonnell et al.	03-07-2000	
	A145	6,040,339	A	Yoshida et al.	03-21-2000	
	A146	6,043,374	A	Widdowson et al.	03-28-2000	
	A147	6,080,763	A	Regan et al.	06-27-2000	
	A148	6,093,742	A	Salituro et al.	07-25-2000	
	A149	6,103,692	A	Avruch et al.	08-15-2000	
	A150	6,114,517	A	Monia et al.	09-05-2000	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 6 of 56

U.S. PATENT DOCUMENTS

	U.S. Patent Document				
A151	6,130,053	A	Thompson et al.	10-10-2000	
A152	6,133,319	A	Widdowson	10-17-2000	
A153	6,136,779	A	Foulkes et al.	10-24-2000	
A154	6,143,764	A	Kubo et al.	11-07-2000	
A155	6,147,107	A	Dent et al.	11-14-2000	
A156	6,147,116	A	Barbachyn et al.	11-14-2000	
A157	6,150,415	A	Hammock et al.	11-21-2000	
A157a	6,159,901	A	Kanno et al.	12-12-2000	
A158	6,174,901	B1	Mantlo et al.	01-16-2001	
A159	6,177,401	B1	Ullrich et al.	01-23-2001	
A160	6,178,399	B1	Takebayashi et al.	01-23-2001	
A161	6,180,631	B1	McMahon et al.	01-30-2001	
A162	6,180,675	B1	Widdowson et al.	01-30-2001	
A163	6,187,799	B1	Wood et al.	02-13-2001	
A164	6,193,965	B1	Karin et al.	02-27-2001	
A165	6,204,267	B1	Tang et al.	03-20-2001	
A166	6,210,710	B1	Skinner	04-03-2001	
A167	6,211,373	B1	Widdowson et al.	04-03-2001	
A168	6,218,539	B1	Widdowson	04-17-2001	
A169	6,228,881	B1	Regan et al.	05-08-2001	
A170	6,235,764	B1	Larson et al.	05-22-2001	
A170a	6,236,125	B1	Oudet et al.	05-22-2001	
A171	6,242,601	B1	Breu et al.	06-05-2001	
A172	6,262,113	B1	Widdowson et al.	07-17-2001	
A173	6,271,261	B1	Widdowson	08-07-2001	
A174	6,294,350	B1	Peterson	09-25-2001	
A175	6,297,381	B1	Cirillo et al.	10-02-2001	
A176	6,310,068	B1	Böttcher et al.	10-30-2001	
A177	6,316,462	B1	Bishop et al.	11-13-2001	
A178	6,319,921	B1	Cirillo et al.	11-20-2001	
A179	6,329,415	B1	Cirillo et al.	12-11-2001	
A180	6,333,341	B1	Mantlo et al.	12-25-2001	

Examiner
Signature

Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 7 of 56

U.S. PATENT DOCUMENTS

	U.S. Patent Document				
A181	6,339,045	B1	Kanno et al.	01-15-2002	
A182	6,344,476	B1	Ranges et al.	02-05-2002	
A183	6,352,977	B1	Astles et al.	03-05-2002	
A184	6,358,525	B1	Guo et al.	03-19-2002	
A185	6,358,945	B1	Breitfelder et al.	03-19-2002	
A186	6,361,773	B1	Lee et al.	03-26-2002	
A187	6,372,773	B1	Regan	04-16-2002	
A188	6,372,933	B1	Baine et al.	04-16-2002	
A189	6,380,218	B1	Marfat et al.	04-30-2002	
A190	6,383,734	B1	Marshall et al.	05-07-2002	
A191	6,387,900	B1	Pevarello et al.	05-14-2002	
A192	6,391,917	B1	Petrie et al.	05-21-2002	
A193	6,403,588	B1	Hayakawa et al.	06-11-2002	
A194	6,414,011	B1	Hogenkamp et al.	07-02-2002	
A195	6,444,691	B1	Oremus et al.	09-03-2002	
A196	6,448,079	B1	Monia et al.	09-10-2002	
A197	6,479,519	B1	Astles et al.	11-12-2002	
A198	6,492,393	B1	Breitfelder et al.	12-10-2002	
A199	6,495,331	B1	Gelfand et al.	12-17-2002	
A200	6,500,863	B1	Jin et al.	12-31-2002	
A201	6,511,800	B1	Singh	01-28-2003	
A202	6,511,997	B1	Minami et al.	01-28-2003	
A203	6,521,407	B1	Warenus et al.	02-18-2003	
A204	6,521,592	B2	Ko et al.	02-18-2003	
A205	6,524,832	B1	Kufe et al.	02-25-2003	
A206	6,525,046	B1	Cirillo et al.	02-25-2003	
A207	6,525,065	B1	Caldwell et al.	02-25-2003	
A208	6,525,091	B2	Robinson et al.	02-25-2003	
A209	6,583,282	B1	Zhang et al.	06-24-2003	
A210	6,608,052	B2	Breitfelder et al.	08-19-2003	
A211	6,617,324	B1	Naraian et al.	09-09-2003	
A212	6,635,421	B1	Klagsbrun et al.	10-21-2003	

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 8 of 56

U.S. PATENT DOCUMENTS

	U.S. Patent Document					
	A213	6,653,320	B2	Hayakawa et al.	11-25-2003	
	A214	6,656,963	B2	Firestone et al.	12-02-2003	
	A215	6,673,777	B1	Tracey et al.	01-06-2004	
	A216	6,689,560	B1	Rapp et al.	02-10-2004	
	A217	6,797,823	B1	Kubo et al.	09-28-2004	
	A217a	6,958,333	B1	Hayama et al.	10-25-2005	
	A218	7,070,968	B2	Kufe et al.	07-04-2006	
	A219	7,235,576	B1	Riedl et al.	06-26-2007	
	A220	7,253,286	B2	Funahashi et al.	08-07-2007	
	A221	7,307,071	B2	Lyons et al.	12-11-2007	
	A222	7,329,670	B1	Dumas et al.	02-12-2008	
	A223	7,351,834	B1	Riedl et al.	04-01-2008	
	A224	7,371,763	B2	Dumas et al.	05-13-2008	
	A225	7,517,880	B2	Miller et al.	04-14-2009	
	A226	7,528,255	B2	Riedl et al.	05-05-2009	
	A226a	7,547,695	B2	Hoelzemann et al.	06-16-2009	
	A227	7,557,129	B2	Scott et al.	07-07-2009	
	A227a	7,605,261	B2	Deprez et al.	10-20-2009	
	A227b	7,612,092	B2	Funahashi et al.	11-03-2009	
	A228	7,678,811	B2	Dumas et al.	03-16-2010	
	B1	2001/0006975	A1	Wood et al.	07-05-2001	
	B2	2001/0011135	A1	Riedl et al.	08-02-2001	
	B3	2001/0011136	A1	Riedl et al.	08-02-2001	
	B4	2001/0016659	A1	Riedl et al.	08-23-2001	
	B5	2001/0027202	A1	Riedl et al.	10-04-2001	
	B6	2001/0034447	A1	Riedl et al.	10-25-2001	
	B7	2001/0038842	A1	Achen et al.	11-08-2001	
	B8	2002/0037276	A1	Ptasznik et al.	03-28-2002	
	B9	2002/0042517	A1	Uday et al.	04-11-2002	
	B10	2002/0062763	A1	Macholdt et al.	05-30-2002	
	B11	2002/0065283	A1	McMahon et al.	05-30-2002	
	B12	2002/0065296	A1	Dumas et al.	05-30-2002	

Examiner
Signature

Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 9 of 56

U.S. PATENT DOCUMENTS

		U.S. Patent Document				
	B13	2002/0082255	A1	Eastwood	06-27-2002	
	B14	2002/0085857	A1	Kim et al.	07-04-2002	
	B15	2002/0085859	A1	Hashimoto et al.	07-04-2002	
	B16	2002/0103253	A1	Ranges et al.	08-01-2002	
	B16a	2002/0111495	A1	Magee et al.	08-15-2002	
	B17	2002/0128321	A1	Widdowson et al.	09-12-2002	
	B18	2002/0137774	A1	Riedl et al.	09-26-2002	
	B19	2002/0161014	A1	Sadhu et al.	10-31-2002	
	B20	2002/0165275	A1	Wu et al.	11-07-2002	
	B21	2002/0165349	A1	Kirsch et al.	11-07-2002	
	B22	2002/0165394	A1	Dumas et al.	11-07-2002	
	B23	2002/0173507	A1	Santora et al.	11-21-2002	
	B24	2002/0188027	A1	Robinson et al.	12-12-2002	
	B25	2002/0197256	A1	Grewal	12-26-2002	
	B26	2003/0069284	A1	Keegan et al.	04-10-2003	
	B26a	2003/0105091	A1	Riedl et al.	06-05-2003	
	B27	2003/0125359	A1	Lyons et al.	07-03-2003	
	B28	2003/0130309	A1	Moss et al.	07-10-2003	
	B29	2003/0144278	A1	Reidl et al.	07-31-2003	
	B30	2003/0157104	A1	Waksal	08-21-2003	
	B30a	2003/0139605	A1	Riedl et al.	07-24-2003	
	B31	2003/0181442	A1	Riedl et al.	09-25-2003	
	B32	2003/0207870	A1	Dumas et al.	11-06-2003	
	B33	2003/0207872	A1	Reidl et al.	11-06-2003	
	B34	2003/0207914	A1	Dumas et al.	11-06-2003	
	B34a	2003/0216396	A1	Dumas et al.	11-20-2003	
	B35	2003/0216446	A1	Dumas et al.	11-20-2003	
	B36	2003/0232400	A1	Radka et al.	12-18-2003	
	B37	2003/0232765	A1	Carter et al.	12-18-2003	
	B37a	2004/0023961	A1	Dumas et al.	02-05-2004	
	B38	2004/0052880	A1	Kobayashi et al.	03-18-2004	
	B39	2004/0096855	A1	Stratton et al.	05-20-2004	

Examiner
Signature

Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	10	of	56	Attorney Docket Number	BAYER-0018-A

U.S. PATENT DOCUMENTS						
		U.S. Patent Document				
	B40	2004/0147541	A1	Lane et al.	07-29-2004	
	B41	2004/0192770	A1	Kozikowski et al.	09-30-2004	
	B42	2004/0197256	A1	Rogers et al.	10-07-2004	
	B43	2004/0209905	A1	Kubo et al.	10-21-2004	
	B43a	2004/0224937	A1	Furness et al.	11-11-2004	
	B44	2004/0229937	A1	Dumas et al.	11-18-2004	
	B45	2004/0235829	A1	Scott et al.	11-25-2004	
	B46	2005/0032798	A1	Boyer et al.	02-10-2005	
	B47	2005/0038031	A1	Dumas et al.	02-17-2005	
	B48	2005/0038080	A1	Boyer et al.	02-17-2005	
	B49	2005/0059703	A1	Wilhelm et al.	03-17-2005	
	B49a	2005/0069963	A1	Lokshin et al.	03-31-2005	
	B49b	2005/0096344	A1	Fraleley et al.	05-05-2005	
	B49c	2005/0175737	A1	Knobel	08-11-2005	
	B50	2005/0256174	A1	Wood et al.	11-17-2005	
	B51	2005/0288286	A1	Flynn et al.	12-29-2005	
	B52	2006/0058358	A1	Dumas et al.	03-16-2006	
	B52a	2006/0241301	A1	Hoelzemann et al.	10-26-2006	
	B52b	2006/0281762	A1	Staehle et al.	12-14-2006	
	B53	2006/0078617	A1	Schueckler	04-13-2006	
	B54	2006/0211738	A1	Mitchell et al.	09-21-2006	
	B55	2006/0234931	A1	Biggs, III et al.	10-19-2006	
	B56	2006/0247186	A1	Carter et al.	11-02-2006	
	B57	2007/0020704	A1	Wilhelm et al.	01-25-2007	
	B57a	2007/0037224	A1	Hamer et al.	02-15-2007	
	B57b	2007/0066660	A1	Stahle et al.	03-22-2007	
	B58	2007/0105142	A1	Wilhelm	05-10-2007	
	B58a	2007/0149594	A1	Finsinger et al.	06-28-2007	
	B59	2007/0173514	A1	Moss et al.	07-26-2007	
	B60	2007/0178494	A1	Elting et al.	08-02-2007	
	B61	2007/0244120	A1	Dumas et al.	10-18-2007	
	B61a	2007/0254295	A1	Harvey et al.	03-16-2007	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	11	of	56	Attorney Docket Number	BAYER-0018-A

U.S. PATENT DOCUMENTS						
		U.S. Patent Document				
	B62	2007/0265315	A1	Dumas et al.	11-15-2007	
	B63	2008/0009527	A1	Dumas et al.	01-10-2008	
	B64	2008/0027061	A1	Riedl et al.	01-31-2008	
	B65	2008/0032979	A1	Riedl et al.	02-07-2008	
	B66	2008/0045546	A1	Bouchon et al.	02-21-2008	
	B67	2008/0045589	A1	Kelley	02-21-2008	
	B68	2008/0085902	A1	Bold et al.	04-10-2008	
	B69	2008/0108672	A1	Riedl et al.	05-08-2008	
	B70	2008/0153823	A1	Riedl et al.	06-26-2008	
	B71	2008/0194580	A1	Dumas et al.	08-14-2008	
	B71a	2008/0207699	A1	Hoelzemann et al.	08-28-2008	
	B72	2008/0214545	A1	Lee et al.	09-04-2008	
	B73	2008/0227828	A1	Dumas et al.	09-18-2008	
	B74	2008/0242707	A1	Schuckler et al.	10-02-2008	
	B75	2008/0262236	A1	Logers et al.	10-23-2008	
	B76	2008/0269265	A1	Miller et al.	10-30-2008	
	B77	2008/0300281	A1	Dumas et al.	12-04-2008	
	B77a	2008/0311601	A1	Elting et al.	12-18-2008	
	B77b	2008/0311604	A1	Elting et al.	12-18-2008	
	B78	2009/0068146	A1	Wilhelm	03-12-2009	
	B79	2009/0093526	A1	Miller et al.	04-09-2009	
	B80	2009/0118268	A1	Riedl et al.	05-07-2009	
	B81	2009/0176791	A1	Sandner et al.	07-09-2009	
	B82	2009/0192127	A1	Scheuring et al.	07-30-2009	
	B83	2009/0215833	A1	Grunenberg et al.	08-27-2009	
	B84	2009/0215835	A1	Wilhelm	08-27-2009	
	B84a	2009/0221010	A1	Elting et al.	09-03-2009	
	B85	2009/0227637	A1	Weber et al.	09-10-2009	
	B86	2009/0306020	A1	Scheuring et al.	12-10-2009	
	B87	2010/0035888	A1	Sandner et al.	02-11-2010	
	B88	2010/0063088	A1	Wood et al.	03-11-2010	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 12 of 56

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ²	Number ³	Kind Code ⁵ (If known)				
	C1	WO	90/02112	A1	The Nutrasweet Company	03-08-1990		
	C2	WO	92/03413	A1	Rhone-Roulenc Rorer Limited et al.	03-05-1992		
	C3	WO	92/05179	A1	American Home Products Corporation	04-02-1992		
	C4	WO	93/04170	A1	The United States of America represented by The Secretary, Department Of Health And Human Services	03-04-1993		
	C5	WO	93/18028	A1	SmithKline Beecham PLC et al.	09-16-1993		
	C6	WO	93/24458	A1	Pfizer Inc. et al.	12-09-1993		
	C7	WO	94/02136	A1	SmithKline Beecham Corp. et al.	02-03-1994		
	C8	WO	94/02485	A1	SmithKline Beecham Corp. et al.	02-03-1994		
	C9	WO	94/04541	A2	The UpJohn Co. et al.	03-03-1994		
	C10	WO	94/14801	A1	SmithKline Beecham PLC et al.	07-07-1994		
	C11	WO	94/18170	A1	SmithKline Beecham PLC et al.	08-18-1994		
	C12	WO	94/22807	A1	Neu-Rosearch, A/S et al.	10-13-1994		
	C13	WO	94/23755	A1	Board of Regents of the University of Nebraska	10-27-1994		
	C14	WO	94/25012	A2	SmithKline Beecham PLC et al.	11-10-1994		
	C15	WO	95/02136	A1	Mannesmann Akteingesellschaft	01-19-1995		abs
	C16	WO	95/02591	A1	SmithKline Beecham Corporation et al.	01-26-1995		
	C17	WO	95/07922	A1	SmithKline Beecham Corporation et al.	03-23-1995		
	C18	WO	95/13067	A1	SmithKline Beecham Corporation et al.	05-18-1995		
	C19	WO	95/14023	A1	Abbott Laboratories	05-26-1995		
	C20	WO	95/16691	A1	Sandoz Ltd. et al.	06-22-1995		
	C21	WO	95/19169	A2	Sugen, Inc.	07-20-1995		
	C22	WO	95/31451	A1	Smithkline Beecham Corporation et al.	11-23-1995		
	C23	WO	95/33458	A1	Smithkline Beecham Corporation et al.	12-14-1995		
	C24	WO	95/33460	A1	Smithkline Beecham Corporation et al.	12-14-1995		
	C25	WO	96/02112	A1	Thomson-CSF et al.	01-25-1996		abs
	C26	WO	96/10559	A1	Fujisawa Pharmaceutical Co., Ltd.	04-11-1996		
	C27	WO	96/13632	A1	Novo Nordisk A/S et al.	05-09-1996		

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 13 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document						
	C28	WO	96/25157	A1	Smith Kline Beecham Corporation et al.	08-22-1996		
	C29	WO	96/40673	A1	Sugen, Inc.	12-19-1996		
	C30	WO	96/40675	A1	Sugen, Inc.	12-19-1996		
	C31	WO	96/41807	A1	Sandoz Ltd. et al.	12-27-1996		
	C32	WO	97/03069	A1	Glaxo Group Limited et al.	01-30-1997		
	C33	WO	97/09973	A2	The Regents of The University of California et al.	03-20-1997		
	C34	WO	97/17267	A1	SCA Mölnlycke AB et al.	05-15-1997		
	C35	WO	97/17329	A1	Kirin Beer Kabushiki Kaisha	05-15-1997		abs
	C36	WO	97/29743	A1	Smith Kline Beecham Corporation et al.	08-21-1997		
	C37	WO	97/30992	A1	Bristol-Myers Squibb Company	08-28-1997		
	C38	WO	97/34146	A1	The General Hospital Corporation	09-18-1997		
	C39	WO	97/40028	A1	Vertex Pharmaceuticals Incorporated	10-30-1997		
	C40	WO	97/40842	A1	Eli Lilly and Company et al.	11-06-1997		
	C41	WO	97/45400	A1	Nen-Rosearch A/S et al.	12-04-1997		
	C42	WO	97/49399	A1	SmithKline Beecham Corporation et al.	12-31-1997		
	C43	WO	97/49400	A1	SmithKline Beecham Corporation et al.	12-31-1997		
	C44	WO	98/17207	A1	Synthes AG Chur et al.	04-30-1998		
	C45	WO	98/17267	A1	Zymogenetics, Inc. et al.	04-30-1998		
	C46	WO	98/20868	A1	The Picower Institute for Medical Research	05-22-1998		
	C47	WO	98/22103	A1	Zeneca Limited et al.	05-28-1998		
	C48	WO	98/22432	A1	Yamanouchi Pharmaceutical Co., Ltd.	05-28-1998		abs
	C49	WO	98/32439	A1	SmithKline Beecham Corporation et al.	07-30-1998		
	C50	WO	98/34929	A1	SmithKline Beecham Corporation et al.	08-13-1998		
	C51	WO	98/45268	A1	Pfizer Products Inc. et al.	10-15-1998		
	C52	WO	98/49150	A1	Takeda Chemical Industries, Ltd. et al.	11-05-1998		
	C53	WO	98/52558	A1	Bayer Corporation et al.	11-26-1998		
	C54	WO	98/52559	A1	Bayer Corporation et al.	11-26-1998		
	C55	WO	98/52937	A2	G.D. Searle and Co. et al.	11-26-1998		
	C56	WO	98/52941	A1	G.D. Searle and Co. et al.	11-26-1998		
	C57	WO	98/56377	A1	SmithKline Beecham Corporation et al.	12-17-1998		
	C58	WO	99/00357	A1	Vertex Pharmaceuticals Incorporated	01-07-1999		

Examiner
Signature

Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 14 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document					
	C59	WO	99/00370	A1	Kureha Kagaku Kogyo Kabushiki Kaisha	01-07-1999	abs
	C60	WO	99/20617	A1	Pharmacia & Upjohn Company et al.	04-29-1999	
	C61	WO	99/21835	A1	Fujisawa Pharmaceutical Co., Ltd. et al.	05-06-1999	
	C62	WO	99/23091	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	05-14-1999	
	C63	WO	99/24035	A1	Bristol-Myers Squibb Company	05-20-1999	
	C64	WO	99/24398	A2	Zeneca Limited et al.	05-20-1999	
	C65	WO	99/24635	A1	Advanced Technology Materials, Inc.	05-20-1999	
	C66	WO	99/26657	A1	Medical University of South Carolina et al.	06-03-1999	
	C67	WO	99/28305	A1	E.I. Dupont De Nemours & Company et al.	06-10-1999	
	C68	WO	99/32106	A1	Bayer Corporation	07-01-1999	
	C69	WO	99/32109	A1	Bristol-Myers Squibb Company	07-01-1999	
	C70	WO	99/32110	A1	Bayer Corporation	07-01-1999	
	C71	WO	99/32111	A1	Bayer Corporation	07-01-1999	
	C72	WO	99/32436	A1	Bayer Corporation	07-01-1999	
	C73	WO	99/32437	A1	Slovak-Farma, A.S. et al.	07-01-1999	
	C74	WO	99/32455	A1	Bayer Corporation	07-01-1999	
	C75	WO	99/32463	A1	Bayer Corporation	07-01-1999	
	C76	WO	99/33458	A1	Daiichi Pharmaceuticals Co., Ltd. et al.	07-08-1999	abs
	C77	WO	99/35132	A1	Glaxo Group Limited et al.	07-15-1999	
	C78	WO	99/40673	A1	Moving Magnet Technologies (S.A.) et al.	08-12-1999	abs
	C79	WO	99/58502	A1	Vertex Pharmaceuticals Incorporated et al.	11-18-1999	
	C80	WO	99/62890	A1	Pfizer Products Inc. et al.	12-09-1999	
	C81	WO	00/12497	A2	Scios Inc. et al.	03-09-2000	
	C82	WO	00/17175	A1	Vertex Pharmaceuticals Incorporated et al.	03-30-2000	
	C83	WO	00/19205	A1	Advanced Research and Technology Institute, Inc. et al.	04-06-2000	
	C84	WO	00/26203	A1	Pharmacia & Upjohn S.P.A. et al.	05-11-2000	

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 15 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document						
	C85	WO	00/27414	A2	BASF Aktiengesellschaft et al.	05-18-2000		
	C86	WO	00/31238	A2	Genetica, Inc. et al.	06-02-2000		
	C87	WO	00/34303	A1	Isis Pharmaceuticals, Inc. et al.	06-15-2000		
	C88	WO	00/35454	A1	Du Pont Pharmaceuticals Company	06-22-2000		
	C89	WO	00/35455	A1	Telik, Inc.	06-22-2000		
	C90	WO	00/39101	A1	Astra Zeneca UK Limited et al.	07-06-2000		
	C91	WO	00/39116	A1	Teikoku Hormone MFG. Co., Ltd.	07-06-2000		abs
	C92	WO	00/41698	A1	Bayer Corporation et al.	07-20-2000		
	C93	WO	00/42012	A1	Bayer Corporation et al.	07-20-2000		
	C94	WO	00/43366	A1	Kirin Beer Kabushiki Kaisha	07-27-2000		abs
	C95	WO	00/43384	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	07-27-2000		
	C96	WO	00/47577	A1	SmithKline Beecham PLC et al.	08-17-2000		
	C97	WO	00/50425	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	08-31-2000		
	C98	WO	00/55139	A2	Boehringer Ingelheim Pharmaceuticals, Inc.	09-21-2000		
	C99	WO	00/55152	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	09-21-2000		
	C100	WO	00/56331	A1	Vertex Pharmaceuticals Incorporated et al.	09-28-2000		
	C101	WO	00/71506	A2	Telik, Inc.	11-30-2000		
	C102	WO	00/71532	A1	Pfizer Products Inc. et al.	11-30-2000		
	C103	WO	01/04115	A2	Boehringer Ingelheim Pharmaceuticals, Inc.	01-18-2001		
	C104	WO	01/07411	A1	Banyu Pharmaceutical Co., Ltd.	02-01-2001		abs
	C105	WO	01/09088	A1	Kirin Beer Kabushiki Kaisha et al.	02-08-2001		
	C106	WO	01/12188	A1	Pharmacia & Upjohn S.P.A. et al.	02-22-2001		
	C107	WO	01/36403	A1	Boehringer Ingelheim Pharmaceuticals, Inc. et al.	05-25-2001		
	C108	WO	01/47892	A1	American Home Products Corporation	07-05-2001		
	C109	WO	01/54723	A1	Sunnybrook Health Science Center et al.	08-02-2001		
	C110	WO	01/54727	A1	The Van Kampen Group, Inc. et al.	08-02-2001		
	C111	WO	01/57008	A1	BASF Aktiengesellschaft et al.	08-09-2001		

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 16 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document						
	C112	WO	01/63403	A2	Sun Microsystems, Inc.	08-30-2001		
	C113	WO	01/66099	A2	Astra Zeneca AB et al.	09-13-2001		
	C114	WO	01/66540	A1	SmithKline Beecham P.L.C. et al.	09-13-2001		
	C114a	WO	01/80843	A2	Supergen, Inc. et al.	11-01-2001		
	C115	WO	02/06382	A1	General Electric Company	01-24-2002		
	C116	WO	02/07747	A1	Joslin Diabetes Center, Inc. et al.	01-31-2002		
	C117	WO	02/07772	A2	Boehringer Ingelheim Pharmaceuticals, Inc.	01-31-2002		
	C118	WO	02/10141	A1	Pfizer Products Inc. et al.	02-07-2002		
	C119	WO	02/114281	A1	Cochran et al.	02-21-2002		
	C120	WO	02/114311	A2	Amgen Inc. et al.	02-21-2002		
	C121	WO	02/18346	A1	Pfizer Products Inc. et al.	03-07-2002		
	C122	WO	02/24635	A2	Fujisawa Pharmaceutical Co., Ltd. et al.	03-28-2002		
	C123	WO	02/25286	A2	The President and Fellows of Harvard College	03-28-2002		
	C124	WO	02/32872	A1	Eisai Co., Ltd.	04-25-2002		abs
	C124-2	WO	02/32872	A1	Eisai Co., Ltd.	04-25-2002		
	C125	WO	02/40445	A1	Novo Nordisk A/S	05-23-2002		
	C126	WO	02/42012	A1	Brill	05-30-2002		
	C127	WO	02/44156	A2	Glaxo Group Limited et al.	06-06-2002		
	C128	WO	02/44158	A1	Pfizer Products Inc. et al.	06-06-2002		
	C129	WO	02/50091	A1	Glaxo Group Limited et al.	06-27-2002		
	C130	WO	02/059081	A2	Padia et al.	08-01-2002		
	C131	WO	02/059102	A2	Aventis Pharma S.A. et al.	08-01-2002		abs
	C132	WO	02/060900	A2	Telik, Inc. et al.	08-08-2002		
	C133	WO	02/062763	A2	Bayer Corporation et al.	08-15-2002		
	C134	WO	02/070008	A1	Imclone Systems Incorporated et al.	09-12-2002		
	C135	WO	02/076930	A2	Telik, Inc.	10-03-2002		
	C136	WO	02/076977	A2	Bayer Corporation et al.	10-03-2002		
	C137	WO	02/083628	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	10-24-2002		
	C138	WO	02/083642	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	10-24-2002		

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 17 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document						
	C139	WO	02/085857	A2	Bayer Corporation et al.	10-31-2002		
	C140	WO	02/085859	A1	Bayer Corporation et al.	10-31-2002		
	C141	WO	02/088090	A2	Vertex Pharmaceuticals Incorporated et al.	11-07-2002		
	C142	WO	02/092576	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	11-21-2002		
	C143	WO	03/004523	A1	Bayer Aktiengesellschaft et al.	01-16-2003		
	C144	WO	03/005999	A2	Boehringer Ingelheim Pharmaceuticals, Inc.	01-23-2003		
	C145	WO	03/047523	A2	Onyx Pharmaceuticals, Inc.	06-12-2003		
	C146	WO	03/047579	A1	Bayer Corporation et al.	06-12-2003		
	C147	WO	03/056036	A2	Catalyst Biomedica Limited et al.	07-10-2003		
	C148	WO	03/059373	A2	Ramot at Tel Aviv University Ltd. et al.	07-24-2003		
	C149	WO	03/060111	A2	Catalyst Biomedica Limited et al.	07-24-2003		
	C150	WO	03/065995	A2	Supergen, Inc. et al.	08-14-2003		
	C151	WO	03/068223	A1	Bayer Corporation et al.	08-21-2003		
	C152	WO	03/068228	A1	Bayer Corporation et al.	08-21-2003		
	C153	WO	03/068229	A1	Bayer Corporation et al.	08-21-2003		
	C154	WO	03/068746	A1	Bayer Corporation et al.	08-21-2003		
	C155	WO	03/082272	A1	Chiron Corporation et al.	10-09-2003		
	C156	WO	03/094626	A1	KMB Produktions AG et al.	11-20-2003		abs
	C156a	WO	03/097854	A2	Sugen, Inc. et al.	11-27-2003		
	C157	WO	03/099771	A2	Novartis AG et al.	12-04-2003		
	C158	WO	2004/004720	A1	Astex Technology Limited et al.	01-15-2004		
	C159	WO	2004/019941	A1	MERCK PATENT GMBH et al.	03-11-2004		
	C160	WO	2004/037789	A2	MERCK PATENT GMBH et al.	05-06-2004		
	C161	WO	2004/043374	A2	Dana-Farber Cancer Institute Inc. et al.	05-27-2004		
	C162	WO	2004/045578	A2	NOVARTIS AG et al.	06-03-2004		
	C163	WO	2004/052880	A1	ASTRAZENECA AB et al.	06-24-2004		
	C164	WO	2004/078128	A2	Bayer Pharmaceuticals Corporation et al.	09-16-2004		
	C165	WO	2004/078746	A2	Bayer Pharmaceuticals Corporation et al.	09-16-2004		

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 18 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document					
	C166	WO	2004/078747	A1	Bayer Pharmaceuticals Corporation et al.	09-16-2004	
	C167	WO	2004/078748	A2	Bayer Pharmaceuticals Corporation et al.	09-16-2004	
	C168	WO	2004/085399	A1	MERCK PATENT GMBH et al.	10-07-2004	
	C169	WO	2004/085425	A1	AMGEN INC.	10-07-2004	
	C170	WO	2004/108713	A1	Warner-Lambert Company LLC et al.	12-16-2004	
	C171	WO	2004/108715	A1	Warner-Lambert Company LLC et al.	12-16-2004	
	C172	WO	2004/113274	A2	Bayer Pharmaceuticals Corporation et al.	12-29-2004	
	C173	WO	2005/000284	A2	Bayer Pharmaceuticals Corporation et al.	01-06-2005	
	C174	WO	2005/002673	A1	Astex Technology Limited et al.	01-13-2005	
	C175	WO	2005/004863	A1	MERCK PATENT GMBH et al.	01-20-2005	
	C176	WO	2005/004864	A1	MERCK PATENT GMBH et al.	01-20-2005	
	C177	WO	2005/005389	A2	MERCK PATENT GMBH et al.	01-20-2005	
	C178	WO	2005/005434	A1	NOVARTIS AG et al.	01-20-2005	
	C179	WO	2005/009367	A2	AMBIT BIOSCIENCES CORPORATION et al.	02-03-2005	
	C180	WO	2005/009961	A2	Bayer Pharmaceuticals Corporation et al.	02-03-2005	
	C181	WO	2005/011700	A1	SMITHKLINE BEECHAM CORPORATION et al.	02-10-2005	
	C182	WO	2005/016252	A2	Ariad Gene Therapeutics, Inc. et al.	02-24-2005	
	C183	WO	2005/019192	A1	MERCK PATENT GMBH et al.	03-03-2005	abs
	C184	WO	2005/032548	A1	CHIRON CORPORATION et al.	04-14-2005	
	C185	WO	2005/037273	A1	CHIRON CORPORATION et al.	04-28-2005	
	C186	WO	2005/037285	A1	CHIRON CORPORATION et al.	04-28-2005	
	C187	WO	2005/037829	A1	MERCK PATENT GMBH et al.	04-28-2005	abs
	C188	WO	2005/042520	A1	MERCK PATENT GMBH et al.	05-12-2005	abs
	C189	WO	2005/047283	A1	MERCK PATENT GMBH et al.	05-26-2005	abs
	C190	WO	2005/048948	A2	Ambit Biosciences Corporation et al.	06-02-2005	
	C191	WO	2005/049603	A1	MERCK PATENT GMBH et al.	06-02-2005	abs
	C191a	WO	2005/056764	A2	Compound Therapeutics, Inc. et al.	06-23-2005	
	C192	WO	2005/058832	A1	MERCK PATENT GMBH et al.	06-30-2005	

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 19 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document						
	C192a	WO	2005/059179	A1	Bayer Pharmaceutical Corporation et al.	06-30-2005		
	C193	WO	2005/075425	A2	MERCK PATENT GMBH et al.	08-18-2005		
	C194	WO	2005/089443	A2	The Penn State Research Foundation et al.	09-29-2005		
	C195	WO	2005/110994	A2	Bayer Pharmaceuticals Corporation et al.	11-24-2005		
	C196	WO	2006/026500	A1	Bayer Pharmaceuticals Corporation et al.	03-09-2006		
	C197	WO	2006/026501	A1	Bayer Pharmaceuticals Corporation et al.	03-09-2006		
	C198	WO	2006/027346	A2	ALTANA PHARMA AG et al.	03-16-2006		
	C199	WO	2006/034797	A1	BAYER HEALTHCARE AG et al.	04-06-2006		
	C200	WO	2006/094626	A1	BAYER HEALTHCARE AG et al.	09-14-2006		
	C201	WO	2006/105844	A1	MERCK PATENT GMBH et al.	10-12-2006		abs
	C202	WO	2006/125540	A1	BAYER HEALTHCARE AG et al.	11-30-2006		
	C203	WO	2007/015947	A2	BAYER HEALTHCARE LLC et al.	02-08-2007		
	C204	WO	2007/039403	A1	ALTANA PHARMA AG et al.	04-12-2007		
	C205	WO	2007/039404	A1	ALTANA PHARMA AG et al.	04-12-2007		
	C205a	WO	2007/047955	A2	BAYER HEALTHCARE LLC et al.	04-26-2007		
	C206	WO	2007/053573	A2	Bayer Pharmaceuticals Corporation et al.	05-10-2007		
	C207	WO	2007/054215	A1	BAYER HEALTHCARE AG et al.	05-18-2007		
	C207a	WO	2007/056011	A2	BAYER HEALTHCARE LLC et al.	05-18-2007		
	C207b	WO	2007/056012	A2	BAYER HEALTHCARE LLC et al.	05-18-2007		
	C208	WO	2007/059094	A2	Bayer Pharmaceuticals Corporation et al.	05-24-2007		
	C209	WO	2007/059154	A2	Bayer Pharmaceuticals Corporation et al.	05-24-2007		
	C210	WO	2007/059155	A1	Bayer Pharmaceuticals Corporation et al.	05-24-2007		
	C211	WO	2007/064872	A2	Bayer Pharmaceuticals Corporation et al.	06-07-2007		
	C212	WO	2007/087575	A2	UNIVERSITY OF CHICAGO et al.	08-02-2007		
	C213	WO	2007/096393	A1	NYCOMED GMBH et al.	08-30-2007		
	C214	WO	2007/096395	A1	NYCOMED GMBH et al.	08-30-2007		

Examiner
Signature

Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 20 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document					
	C215	WO	2007/123722	A2	Bayer Pharmaceuticals Corporation et al.	11-01-2007	
	C216	WO	2007/139930	A2	Bayer Pharmaceuticals Corporation et al.	12-06-2007	
	C217	WO	2008/055966	A1	ABBOTT GMBH & CO. KG et al.	05-15-2008	
	C218	WO	2008/079968	A1	Bayer Pharmaceuticals Corporation et al.	07-03-2008	
	C219	WO	2008/079972	A2	Bayer Pharmaceuticals Corporation et al.	07-03-2008	
	C220	WO	2008/089389	A2	Bayer Pharmaceuticals Corporation et al.	07-24-2008	
	C221	WO	2009/034308	A2	Cipla Limited et al.	03-19-2009	
	C222	WO	2009/054004	A2	Nateo Pharma Limited et al.	04-30-2009	
	D1	EP	0016371	A1	F. Hoffman-La Roche & Co. Aktiengesellschaft	10-01-1980	abs
	D2	EP	0107214	A2	Duphar International Research B.V.	05-02-1984	
	D3	EP	0116932	A1	BASF Aktiengesellschaft	08-29-1984	abs
	D3a	EP	0192263	B1	Ishihara Sangyo Kaisha Ltd. et al.	07-29-1992	
	D4	EP	0192263	A2	Ishihara Sangyo Kaisha Ltd. et al.	08-27-1986	
	D5	EP	0202538	A1	Bayer AG	11-26-1986	abs
	D6	EP	0230400	A2	CIBA-GEIGY AG	07-29-1987	abs
	D6a	EP	0233559	A1	Ishihara Sangyo Kaisha Ltd. et al.	08-26-1987	
	D7	EP	0233559	B1	Ishihara Sangyo Kaisha Ltd. et al.	05-06-1992	
	D8	EP	0242666	A1	BASF Aktiengesellschaft	10-28-1987	abs
	D9	EP	0264904	A2	Ishihara Sangyo Kaisha Ltd. et al.	04-27-1988	
	D10	EP	0314615	A2	Ciba-Geigy AG	05-03-1989	abs
	D11	EP	0335156	A1	Bayer AG	10-04-1989	abs
	D12	EP	0359148	A1	Ishihara Sangyo Kaisha, Ltd. et al.	03-21-1990	
	D13	EP	0371876	A1	Novapharne	06-06-1990	abs
	D14	EP	0379915	A1	Bayer AG	08-01-1990	abs
	D15	EP	0380048	A2	Ishihara Sangyo Kaisha, Ltd.	08-01-1990	
	D16	EP	0381987	A1	Ishihara Sangyo Kaisha, Ltd. et al.	08-16-1990	
	D17	EP	0405233	A1	Mitsubishi Kasei Corporation	01-02-1991	
	D18	EP	0425443	A1	Ciba-Geigy AG	05-02-1991	abs

Examiner
Signature

Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 21 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document					
	D19	EP	0459887	A1	Novapharme	12-04-1991	abs
	D20	EP	0502504	A1	Matsushita Electric Industrial Co., Ltd.	09-09-1992	
	D21	EP	0509795	A2	American Home Products Corporation	10-21-1992	
	D22	EP	0676395	A2	Hoechst Aktiengesellschaft	10-11-1995	abs
	D23	EP	0690344	A1	Konica Corporation	01-03-1996	
	D24	EP	0709220	A1	Canon Kabushiki Kaisha	05-01-1996	
	D24a	EP	0709225	A1	Nippon Paper Industries Co., Ltd.	05-01-1996	
	D25	EP	0709225	B1	Nippon Paper Industries Co., Ltd.	08-05-1998	
	D26	EP	0860433	A1	Kirin Beer Kabushiki Kaisha	08-26-1998	
	D27	EP	1056725	A1	Bayer Corporation	12-06-2000	
	D28	EP	1199306	A1	Banyu Pharmaceutical Co., Ltd.	04-24-2002	
	D29	EP	1256587	A1	The Kitasato Institute	11-13-2002	
	D30	EP	1537075	A0	Neurosearch A/S et al.	06-08-2005	
	E1	CH	479557		Dr. A. Wander AG	11-28-1969	abs
	F1	CL	38688		Ciba-Geigy AG	06-04-1993	
	G1	CA	2 146 707	A1	Hoechst Aktiengesellschaft	10-12-1995	
	G2	CA	2,028,536	A1	Ciba-Geigy AG	04-28-1991	
	H1	DD	253997	A1	Karl-Marx-Universität, Büro Für Neuerungen und Schutzrechte	02-10-1988	abs
	I1	DE	487014	C1	I.G. Farbenindustrie Akt.-Ges.	11-14-1929	
	I2	DE	511468	C1	I.G. Farbenindustrie Akt.-Ges.	10-16-1930	abs
	I3	DE	523437	C1	I.G. Farbenindustrie Akt.-Ges.	04-02-1931	
	I4	DE	2436179	C2	Shionogi & Co. Ltd.	04-10-1986	abs
	I5	DT	2501648	A1	The Dow Chemical Co.	07-24-1975	abs
	I6	DT	2436179	A1	Shionogi & Co., Ltd.	02-06-1975	abs
	I7	DE	3305866	A1	BASF AG	08-23-1984	abs
	I8	DE	3529247	A1	Bayer AG	11-20-1986	abs
	I9	DE	3540377	A1	Bayer AG	05-21-1987	abs
	J1	FR	1,457,172	A	Ferrania S.p.A.	09-19-1966	abs
	K1	GB	771,333		J.R. Geigy A.-G.	03-27-1957	
	K2	GB	828,231		J.R. Geigy A.-G.	02-17-1960	
	K3	GB	921,682		J.R. Geigy A.-G.	03-20-1963	

Examiner
Signature

Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd Riedl et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-0018-A

Sheet 22 of 56

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document						
	K4	GB	1,110,099		Rhone- Poulenc S.A.	04-18-1968		
	K4a	GB	1,111,554		Societa Per Azioni Ferrania	05-01-1968		
	K5	GB	1 590 870		Shionogi Seiyaku Kabushiki Kaisha.	06-10-1981		
	L1	HU	P0004437		Bayer Corporation	06-28-2001		abs
	M1	IR	26555		Bayer Corporation			abs
	N1	JP	44-2569	B	Sankyo Co., Ltd. and Asahi Chem. Ind. Co., Ltd	02-03-1969		abs
	N2	JP	50-76072	A	Shionogi Seiyaku KK	06-21-1975		abs
	N3	JP	50-77375	A	Shionogi Seiyaku KK	06-24-1975		abs
	N4	JP	50-149668	A	unknown	11-29-1975		abs
	N5	JP	51-63170	A	Shionogi Shinzaburo	06-01-1976		abs
	N6	JP	51-80862	A	Shionogi Seiyaku KK	07-15-1976		abs
	N7	JP	53-86033	A	Shionogi Co. Ltd.	07-29-1978		abs
	N8	JP	54-32468	A	Otsuka Pharmaceutical Co. Ltd.	09-03-1979		abs
	N9	JP	55-98152	A	HOKKO CHEM. IND. CO.	07-25-1980		abs
	N10	JP	55-124763	A	Ishihara Mining & Chemical Co.	09-26-1980		abs
	N11	JP	55-162772	A	Shionogi & Co. Ltd.	12-18-1980		abs
	N13	JP	57-53785	B2	Shionogi Seiyaku KK	11-15-1982		abs
	N14	JP	58-21626	B2	Shionogi Seiyaku KK	05-02-1983		abs
	N16	JP	61-20039	A	Konishiroku Photo Ind. Co., Ltd.	01-28-1986		abs
	N15	JP	63-214752	A	Fuji Photo Film Co. Ltd.	09-07-1988		abs
	N17	JP	64-9455	A	Fuji Photo Film Co., Ltd.	01-12-1989		abs
	N18	JP	1-102461	A	Konica Corp.	04-20-1989		abs
	N19	JP	1-132580	A	Ciba Geigy AG	05-25-1989		abs
	N20	JP	1-200254	A	Konica Corp.	08-11-1989		abs
	N21	JP	1-259360	A	Konica Corp.	10-17-1989		abs
	N22	JP	2-22650	A	Konica Corp.	01-25-1990		abs
	N23	JP	2-23337	A	Konica Corp.	01-25-1990		abs
	N24	JP	2-35450	A	Konica Corp.	02-06-1990		abs
	N25	JP	2-105146	A	Konica Corp.	04-17-1990		abs
	N26	JP	2-108048	A	Konica Corp.	04-19-1990		abs
	N27	JP	2-150840	A	Konica Corp.	06-11-1990		abs

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	23	of	56	Attorney Docket Number	BAYER-0018-A

FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document					
	N28	JP	3-53247	A	Fuji Photo Film Co. Ltd.	03-07-1991	abs
	N29	JP	3-144634	A	Konica Corp.	06-20-1991	abs
	N30	JP	3-198049	A	Fuji Photo Film Co. Ltd.	08-29-1991	abs
	N31	JP	6-75172	B2	Fuji Photo Film Co. Ltd.	09-21-1994	abs
	N32	JP	8-301841	A	Green Cross Corp. et al.	11-19-1996	abs
	N33	JP	10-306078	A	Mitsubishi Chemical Corp.	11-17-1998	abs
	O1	LB	6124		Bayer Corporation.	Unknown	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	P1	Adjei et al., "A Phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)," Abstract #3067, Meeting: 2005 ASCO Annual Meeting, Category: Developmental Therapeutics: Molecular Therapeutics, Subcategory: Antiangiogenic or Antimetastatic agents		
	P2	Ahmad et al., "Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma," <i>Clinical Cancer Research</i> , September 15, 2004, Vol. 10(suppl.), pp. 6388s-6392s		
	P3	Amornphimoltham et al., "Persistent Activation of the Akt Pathway in Head and Neck Squamous Cell Carcinoma: A Potential Target for UCN-01," <i>Clinical Cancer Research</i> , Vol. 10, June 15, 2004, pp. 4029-4037		
	P3a	Arzneimitteltherapie, "Sorafenib" October 6, 2006, Auflage 18498, 7 pages		
	P4	Arnove et al., "Selectivities in the Oxidation of Tertiary Amines and Pyridine Derivatives by Perfluoro Cis-2,3-dialkyloxaziridines," <i>Tetrahedron</i> , Vol. 54, 1998, pp. 7831-7842		
	P4a	Arora et al., "Stromelysin 3, Ets-1, and Vascular Endothelial Growth Factor Expression in Oral Precancerous and Cancerous Lesions: Correlation with Microvessel Density, Progression, and Prognosis," <i>Clinical Cancer Research</i> , 11: 2272-2284 (March 15, 2005)		
	P4b	Ascierto et al., "Prognostic Value of Serum VEGF in Melanoma Patients: a Pilot Study" <i>Anticancer Research</i> , 24: 4255-4258 (2004)		
	P5	Auclair et al., "BAY 43-9006 (Sorafenib) is a potent inhibitor of FLT3 tyrosine kinase signaling and proliferation in AML cells," Abstract #5991, 96 th Annual Meeting, Anaheim/Orange County, CA, April 16-20, 2005		
	P6	Audia et al., "Potent, Selective Tetrahydro- β -carboline Antagonists of the Serotonin 2B (5HT _{2B}) Contractile Receptor in the Rat Stomach Fundus," <i>J. Med. Chem.</i> 1996, 39, pp. 2773-2780		
	P7	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway," <i>TIBS</i> 19; July 1994; pp. 279-283		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	24	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ⁶
	P8	Awada et al., "Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours" British Journal of Cancer 92, pp.1855-1861 (2005).	
	P8a	Bachelot et al., "Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients," British Journal of Cancer, 88: 1721-1726 (2003)	
	P9	Badger et al., "Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function," JPET 279: pp. 1453-1461 (1996)	
	P9a	Baka et al., "A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis," Expert Opinion Therapeutic Targets, 2006, Vol. 10, No.6, pp. 867-876	
	P10	Balant et al., "Metabolic Considerations in Prodrug Design," Chapter Twenty-Three In: Burger's Medicinal Chemistry and Drug Discovery, 5 th ed. John Wiley & Sons, Inc., New York, 1995: Vol. 1, pp. 949-982	
	P11	Bando et al., "Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer" British Journal of Cancer, 2005, Vol. 92, pp. 553-561	
	P12	Banerjee et al., "Murine Coronavirus Replication-Induced p38 Mitogen-Activated Protein Kinase Activation Promotes Interleukin-6 Production and Virus Replication in Cultured Cells," Journal of Virology, American Society for Microbiology, 2002: Vol. 76, pp. 5937-5948	
	P13	Bankston et al., "A Scalable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer," Organic Process Research & Development, 2002, Vol. 6, pp. 777-781	
	P14	Barnett et al., "Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors," Biochem J., Vol. 385, 2005, pp. 399-408	
	P14a	Baumann et al., "Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation," Proc. Natl. Acad. Sci. USA, Vol. 97: No. 9: 4615-4620 (April 25, 2000)	
	P15	Bayer Corporation et al., "Trial of BAY 43-9006 in Patients with Relapsed or Refractory Advanced Non-Small Cell Lung Carcinoma", NCT0010413, clinicaltrials.gov, 3 pages	
	P16	Bellacosa et al., "Molecular Alterations Of The AKT2 Oncogene In Ovarian And Breast Carcinomas," Int. J. Cancer (Pred. Oncol.), Vol. 64, 1995, pp. 280-285	
	P17	Berge et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, January 1977:1-19, Vol. 66, No. 1	
	P18	Bergstrahl et al., "Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination," Cancer Treatment Reviews, 2006, Vol. 32, pp. 166-179	
	P19	Bertrand et al., "Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-Lineage ALL in the presence of stromal cell support", Leukemia, Vol. 19, pp. 98-102 (published online October 21, 2004)	
	P20	Bhagwat et al., "The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis," Blood, Vol. 101, No. 5, pp. 1818-1826, (March 1, 2003)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	25	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹ 6
	P21	Bianchi et al., "A Phase II multi-center uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer" Journal of Clinical Oncology. Draft 33 pages (presented previously Oct. 30-Nov. 3, 2005).	
	P22	Martin-Blanco, "p38 MAPK signalling cascades: ancient roles and new functions," BioEssays, 22:637-645, 2000	
	P23	Foussard-Blanpin, Odette, "Comparative pharmacological study of substituted carboxamides upon central nervous system." Ann. Pharm. Fr. (1982), 40 (4), pp. 339-350	abs
	P24	Board et al., "Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics," Drug Resistance Updates 8 (2005) 75-83.	
	P24a	Bok et al., "Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study," Cancer Research, 61: 2533-2536 (March 15, 2001)	
	P25	Bollag et al., "Raf pathway inhibitors in oncology," Current Opinion in Investigational Drugs (2003) 4(12): pp. 1436-1441.	
	P26	Bolton et al., "Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy," Annual Reports In Medicinal Chemistry, Vol. 29, 1994, pp. 165-174	
	P26a	Bono et al., "Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib," Blood 103:2929-2935 (2004)	
	P27	Bos, J.L. "ras Oncogenes in Human Cancer: A Review," Cancer Research, Vol. 49, September 1, 1989, pp. 4682-4689	
	P28	Boulton et al., "Heterocyclic Rearrangements. Part X. A Generalised Monocyclic Rearrangement," J. Chem. Soc. (C), 1967, pp. 2005-2007	
	P28a	Boyer, S.J., "Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activity Relationships," Current Topics in Medicinal Chemistry, 2002, Vol. 2, pp. 973-1000	
	P29	Boyd, et al. "Arene Oxides Of Quinoline: Epoxidation, N-Oxidation And N-Methylation Reactions," J. Chem. Soc. Perkin Trans. I, 1991: pp. 2189-2192	
	P29a	Braybrooke et al., "A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis," Clin. Canc. Res. 6:4697-4704 (2000)	
	P29b	Broll et al., "Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer?" Eur. J. Surg. Oncol. 27:37-42 (2001)	
	P30	Bruder et al., "Adenovirus Infection Stimulates The Raf/MAPK Signaling Pathway and Induces Interleukin-8 Expression" Journal of Virology, Vol. 71, pp. 398-404, 1997	
	P31	Bundgaard, Hans. "Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities." pp. 1-92, in Design of Prodrugs, Elsevier Science Publishers B.V., Amsterdam, The Netherlands, 1985	
	P32	Campbell et al., "Increasing complexity of Ras signaling," Oncogene, 1998, Vol. 17, pp. 1395-1413	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	26	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	^{1,6}
	P33	Cancer Weekly, "Antisense Technology (Clinical Trial). Phase II Trial of Second Antisense Cancer Drug Begins." Cancer Weekly, p. 4 (December 8, 1997).	
	P34	Canetta et al., "Carboplatin: current status and future prospects," Cancer Treatment Reviews, 1998, pp. 17-32, vol. 15(Supplement B)	
	P34a	Caponigro et al., "Epidermal growth factor receptor as a major anticancer drug target," Exp. Opin. Thera. Targets, 2006, Vol. 10, No. 6, pp. 877-888	
	P35	Carey et al., "Contents of Part A," pp. vii-xi and "Contents of Part B," pp. xiii-xviii, in Advanced Organic Chemistry, Second Edition, Part A: Structure and Mechanisms, Plenum Press, NY (1984)	
	P36	Carling et al., "1-(3-Cyanobenzyl)piperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D ₄ Receptor with Excellent Selectivity over Ion Channels," J. Med. Chem., 1999, 42, pp. 2706-2715	
	P37	Carlomagno et al., "BAY 43-9006 Inhibition of Oncogenic RET Mutants," Journal of the National Cancer Institute, 2006, Vol. 98, No. 5, pp. 326-334	
	P37a	Carney et al., "Monitoring the Circulating Levels of the HER2/ <i>neu</i> Oncoprotein in Breast Cancer," Clin Breast Cancer 5(2): 105-116, (2004)	
	P38	Carter et al., "Anti-Tumor Efficacy of the Orally Active <i>Raf</i> Kinase Inhibitor BAY 43-9006 in Human Tumor Xenograft Models," Proceedings of the American Association for Cancer Res., Vol. 42: p. 923, March 2001, Abstract #4954	
	P39	Carter et al., "Drug-Tumor Interactions" pp. 362-365, in: Chemotherapy of Cancer, Second Edition, John Wiley & Sons, NY (1981)	
	P40	Carter et al., "Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma," Cancer Chemotherapy and Pharmacology, Springer Berlin/Heidelberg, Vol.59, No.2, pp. 183-195 (February 2007). Abstract.	
	P41	Chang et al., "BAY 43-9006 (Sorafenib) inhibits ectopic (s.c.) and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis," 96 th Annual Meeting, Anaheim/Orange County, CA, April 16-20, 2005, 1 page.	
	P42	Chang et al., "Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models," Cancer Chemother. Pharmacol., 2007, Vol. 59, pp. 561-574	
	P43	Chen et al., "Role of Regulatory Elements and the MAPK/ERK OR p38 MAPK Pathways for Activation of Human Cytomegalovirus Gene Expression," Journal of Virology, 2002: Vol. 76, No. 10, pp. 4873-4885	
	P44	Chen et al., "Suppression of Japanese encephalitis virus infection by non-steroidal, anti-inflammatory drugs," Journal of General Virology, 2002, Vol. 83, pp. 1897-1905	
	P44a	Chen et al., "Expression of Proinflammatory and Proangiogenic Cytokines in Patients with Head and Neck Cancer," Clinical Cancer Research 5:1369-1379 (June 1999)	
	P45	Chialda et al., "Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia," Respiratory Research 2005, 6:36, pp.1-19	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	27	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P45a	Chin et al., "Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence," <i>European Journal of Surgical Oncology</i> , 29:497-505 (2003)	
	P46	Choi et al., "Imatinib-Resistant Cell Lines Are Sensitive to the Raf Inhibitor BAY 43-9006," <i>Blood</i> , W.E.B. Saunders Company, Orlando, FL, US, Vol. 100, No. 11, Abstract # 1427 (December 10, 2002)	
	P46a	Choong et al., "Forthcoming receptor tyrosine kinase inhibitors," <i>Exp. Opin. Ther. Targets</i> , 2006, Vol. 10, No. 6, pp. 793-797	
	P47	Chow et al., "Measurement of MAP Kinase Activation by Flow Cytometry Using Phospho-Specific Antibodies to MEK and ERK: Potential for Pharmacodynamic Monitoring of Signal Transduction Inhibitors," <i>Cytometry (Communications in Clinical Cytometry)</i> 46:72-78 (2001)	
	P47a	Christensen, et al., "Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor," <i>Mol. Cancer Ther.</i> , 4(6):938-947 (June 2005)	
	P47b	Chu et al., "Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib," <i>Lancet</i> , 2007, Vol. 370, pp.2011-2019	
	P48	Chustecka et al., "Bortezomib and Sorafenib Show Activity in Thyroid Cancer," <i>Medscape</i> , 2 pages (November 2, 2006)	
	P49	Clark et al., "Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors," <i>Clinical Cancer Res.</i> , August 1, 2005, Vol. 11, Number 15, pp. 5472-5480	
	P49a	Garbe, "Auch ein Therapieplatz für Sorafenib?" <i>Medical Special</i> (2006) 2 pages	
	P50	Copéret et al., "A Simple And Efficient Method for the Preparation of Pyridine-N-oxides II," <i>Tetrahedron Letters</i> , Elsevier Science Ltd., Pergamon Press, Oxford, UK 1998: Vol. 39, pp. 761-764	
	P51	Cortes et al., "Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones," <i>The Oncologist</i> , 2007, Vol. 12, pp. 271-280	
	P52	Craig, "The mechanisms of drug release from solid dispersions in water-soluble polymers," <i>International Journal of Pharmaceutics</i> 231 (2002) 131-144, Elsevier Science B.V.	
	P53	Le Cras et al., "Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure," <i>Am. J. Physiol. Lung. Cell. Mol. Physiol.</i> Vol. 283, pp. L555-L562, 2002.	
	P53a	Crump, Micheal, "Inhibition of raf kinase in the treatment of acute myeloid leukemia," <i>Medline Abstract</i> ISSN:1381-6128, <i>Current Pharmaceutical Design</i> , Vol. 8, Issue 25, 2002, pp. 2243-2248	
	P54	Cunningham et al., "A Phase I Trial of H-ras Antisense Oligonucleotide ISIS 2503 Administered as a Continuous Intravenous Infusion in Patients with Advanced Carcinoma," <i>Cancer</i> , 2001, American Cancer Society, Vol. 92, Number 5, pp. 1265-1271	
	P55	Danson et al., "Improving Outcomes in Advanced Malignant Melanoma. Update on Systemic Therapy," <i>Drugs</i> , 2005, Vol. 65, Number 6, pp. 733-743	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	28	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹ 6
	P56	Dasmahapatra et al., "In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines." Clinical Cancer Research, Vol. 10, August 1, 2004, pp. 5242-5252.	
	P57	Daum et al., "The ins and outs of Raf kinases," TIBS 19, November 1994, pp. 474-480	
	P58	Dayan et al., "Tertiary Amine Oxidation using HOF-CH ₃ CN: A Novel Synthesis of N-Oxides," Synthesis, 1999, No. SI, pp. 1427-1430	
	P59	DeGrendele, "Activity of the Raf Kinase Inhibitor BAY 43-9006 in Patients with Advanced Solid Tumors," Clinical Colorectal Cancer, May 2003, Vol. 3, pp. 16-18	
	P59a	Dehtling, J. "Große Onkologie-Pipeline" Medizinische Monatsschrift für Pharmazeuten, 2006, Auflage 12914, 2 pages	
	P60	Denny, "Prodrug strategies in cancer therapy," European Journal Of Medicinal Chemistry, 2001: Vol. 36, pp. 577-595	
	P60a	DeVita et al., "Elevated Perioperative Serum Vascular Endothelial Growth Factor Levels in Patients with Colon Carcinoma," Cancer, 100 (2) pp. 270-278 (2004)	
	P61	Devlin et al., "GATT and DISCOVERY: Significant Changes in U.S. Patent Law" Screening Forum, Vol. 3, No. 4, pp. 1, 3 and 6 (December 1995).	
	P62	Doanes et al., "VEGF Stimulates MAPK through a Pathway That Is Unique for Receptor Tyrosine Kinases," Biochem Biophys. Res. Commun. 255: pp. 545-548, 1999.	
	P63	Dörwald, "Preface," p. IX, in Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Wiley-VCH Verlag GmbH & Co. KGaA (2005)	
	P64	Downward, J., "Mechanisms and consequence of activation of protein kinase B/Akt," Current Opinion in Cell Biology, Vol. 10, 1998, pp. 262-267.	
	P64a	Dreys et al., "Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials," Annals of Oncology, 16: 558-565 (2005)	
	P64b	Dreys, J., "Soluble Markers for the Detection of Hypoxia under Antiangiogenic Treatment," Anticancer Research, 23: 1159-1162 (2003)	
	P64c	Dreys, J., Die Medizinische Welt, 2006, pp. 3/5, 4/5, 5/5	
	P65	"Doxorubicin HCl (ADR)," in drugs: facts and comparisons, 1994 Ed., pp. 2703-2705	
	P65a	Dudek et al., "Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival," Cancer Investigation, 23: 193-200 (2005)	
	P66	Dumas, J. "Protein kinase inhibitors from the urea class," Curr. Opin. in Drug Discovery and Dev., 5(s):718-727, 2002	
	P67	Dumas et al., "Discovery of a New Class of p38 Kinase Inhibitors," Bioorganic & Medicinal Chemistry Letters Vol. 10, (2000), pp. 2047-2050	
	P68	Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors," Bioorganic & Medicinal Chemistry Letters, 2000, Vol. 10, pp. 2051-2054	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	29	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P68a	Dumas, J., "Growth factor receptor kinase inhibitors: Recent progress and clinical impact," Current Opinion in Drug Discovery & Development, 2001, Vol. 4, No. 4, pp. 378-389	
	P68b	Dumas, J., "Protein kinase inhibitors: emerging pharmacophores 1997-2000," Expert Opinion on Therapeutic Patents (2001) Vol. 11, No. 3, pp. 405-429	
	P68c	Dumas et al., "Orally Active p38 Kinase Inhibitors from the Urea Class," Poster, 222nd American Cancer Society National Meeting 2001, Med 1 256, 1 page	
	P68d	Dumas, J., "Raf Kinase Inhibitors," Expert Opinion on Therapeutic Patients, Vol. 8, No. 12, pp. 1749-1750, 1998	
	P69	Dumas et al., "Recent developments in the discovery of protein kinase inhibitors from the urea class," Current Opinion in Drug Discovery & Development, 2004, Vol. 7, Number 5, pp. 600-616	
	P70	Dumas et al., "Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor," Bioorganic & Medicinal Chemistry Letters, 2002, Vol. 12, pp. 1559-1562	
	P70a	Dunst et al., "Tumor Hypoxia and Systemic Levels of Vascular Endothelial Growth Factor (VEGF) in Head and Neck Cancers," Strahlentherapie und Onkologie, 177(9): 469-473 (2001)	
	P71	Ebos et al., "Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlated with antitumor efficacy" PNAS Vol. 104, No. 43, pp. 17069-17074 (October 23, 2007)	
	P71a	Ebrahimi et al., "Cytokines in Pancreatic Carcinoma. Correlation with Phenotypic Characteristics and Prognosis." Cancer, 101(12): 2727-2736 (Published on-line Nov 3, 2004)	
	P72	Eisen et al., "Phase I trial of BAY 43-9006 (Sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients." Abstract #7508, Meeting: 2005 ASCO Annual Meeting. Category: Melanoma, Subcategory: Melanoma	
	P73	Eisen et al., "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis" British Journal of Cancer 95, 581-586 (2006)	
	P74	Eisenhauer et al., "Impact of new non-cytotoxics in the treatment in ovarian cancer," International J. Gynecol. Cancer, 2001, Vol. 11, Supplement 1, pp. 68-72	
	P75	El-Deiry, Wafik S., "Meeting Report: The International Conference on Tumor Progression and Therapeutic Resistance", Cancer Research, 2005; Vol. 65, No. 11, pp. 4475-4484	
	P76	Elting et al., "Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma," Proc. Amer. Assoc. Cancer Res. Vol. 47, Abstract # 2909, 2006, pp. 683-684	
	P77	Escudier et al., "Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)," Meeting: 2005 ASCO Annual Meeting. Category: Genitourinary Cancer, Subcategory: Kidney Cancer, 1 page.	
	P78	Escudier et al., "Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma" New England Journal of Medicine Vol. 356: 125-134 (January 11, 2007).	
	P79	European Medicines Agency, "CHMP Assessment Report for Nexavar" Doc Ref: EMEA/CHMP/140610/2006, 63 pages.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	30	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	^{1,6}
	P79a	Fabian et al., "A small molecule-kinase interaction map for clinical kinase inhibitors," Nature Biotechnology, 2005, Vol. 23, No. 3, pp 329-336, 4 supplementary pages	
	P79b	Faderl et al., "Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia," Blood, 2005 Vol. 106 No. 13, pp. 4303-4307	
	P80	Faivre et al., "Molecular basis for sunitinib efficacy and future clinical development" Nature Reviews Drug Discovery, Nature Publishing Group, pp. 734-745, Vol. 6 (September 2007)	
	P80a	Fakhari et al., "Upregulation of Vascular Endothelial Growth Factor Receptors is Associated with Advanced Neuroblastoma," Journal of Pediatric Surgery, 37(4): 582-587 (April 2002)	
	P81	Favaro et al., "Targeted therapy in renal cell carcinoma," Expert Opin. Investig. Drugs 14(10):1251-1258 (2005)	
	P81a	Fiedler et al. "A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia," Blood, 102(8): 2763-2767(prepublished online Jul. 3, 2003)	
	P82	Feldmann, "Pathogenesis of arthritis: recent research progress," Nature Immunology 2001, Vol. 2, No. 9, pp. 771-773.	
	P83	Fields Virology Second Editon, "Contents," Vol.1, pp. ix-xiv, Raven Press, NY (1990)	
	P84	Flaherty et al., "A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel" Clin Cancer Res 41(15):4836-4842 (August 1, 2008).	
	P85	Flaherty et al., "Phase I/II trial of Bay 43-9006 carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma." Journal of Clinical Oncology, 2004 ASCO annual meeting proceedings, Vol. 22, No. 14S (2004) Supplement: 7507, 4 pages	
	P85a	Flaherty et al., "Antisense therapeutics: lessons from early clinical trials," Current Opin. in Oncol. 13: 499-505 (2001)	
	P86	Foekens et al., "High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer." Cancer Research, 2001, Vol. 61, pp. 5407-5414	
	P87	Forbes et al., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," Journal of Medicinal Chemistry, 1995, Vol. 38, No. 6, pp. 855-857	
	P88	Franco et al., "Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions," International Journal of Pharmaceutics 225 (2001) pp. 63-73	
	P89	Fridman et al., "The Minimal Fragments of c-Raf-1 and NFI That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, Vol. 269, no. 48, 1994, pp. 30105-30108	
	P90	Garcia-López et al., "New Routes for the Synthesis of Pyrrolo[3,2-d]- and [2,3-d]-pyrimidine Systems starting from a Common Pyrrole Derivative." Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1978, pp. 483-487	
	P91	Gatzemeier et al., "Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma," Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part 1, Vol. 24, No. 18S (June 20 Supplement) 2006, abstract no. 7002, 4 pages.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	31	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹ 6
	P92	Geiger et al., "Antitumor Activity of a C-raf Antisense Oligonucleotide in Combination with Standard Chemotherapeutic Agents against Various Human Tumors Transplanted Subcutaneously into Nude Mice," Clinical Cancer Research Vol. 3, 1179-1185, July 1997	
	P93	Geng et al., "A Specific Antagonist of the p110δ Catalytic Component of Phosphatidylinositol 3'-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction," Cancer Research, 64, July 2004, pp. 4893-4899	
	P94	Gennaro, Alfonso R. "Table of Contents," pp. xiv-xv, in Remington: The Science and Practice of Pharmacy, 20TH Ed. Remington. Lippincott Williams & Wilkins, 2000	
	P94a	George et al., "VEGF-A, VEGF-C and VEGF-D in Colorectal Cancer Progression," Neoplasia, 3(5): 420-427 (2001)	
	P94b	George et al., "Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480," Clinical Cancer Research, 7: 1932-1936 (July 2001)	
	P95	Abou-Alfa et al., "Phase II Study of Sorafenib in Patients with Advanced Hepatocellular Carcinoma" Journal of Clinical Oncology, Vol. 24, No. 26, pp. 4293-4300 (September 10, 2006).	
	P96	Giambartolomei et al., "Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein," Oncogene, Nature Publishing Group, 2001: Vol 20, pp. 2606-2610	
	P97	Gills et al., "The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt," Expert Opin. Investig. Drugs, Vol. 13, No. 7, 2004, pp. 787-797	
	P98	Gollob, "Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma" Pub Med PMID: 16425993, Clin. Genitourin. Cancer 4(3):167-174 (2005) abstract.	
	P99	Gómez-Esquer et al., "mRNA expression of the angiogenesis markers VEGF and CD105 (endoglin) in human breast cancer," Anticancer Res., 2004, Vol. 24, No. 3a, pp. 1581-1585, XP-002455577, abstract.	
	P100	Grant et al., "Some Hypotensive Thiadiazoles," J. Med. Chem. (1972), 15(10), pp. 1082-1084	
	P101	Greene et al., "Contents," pp. xi-xii, in: Protective Groups in Organic Synthesis, 3rd Ed. John Wiley & Sons, Inc., New York, 1999	
	P102	Gelasser, "The Importance of Solvates," in: Polymorphism in the Pharmaceutical Industry, Chapter 8, p. 211, 2006, Wiley-VCH Verlag GmbH & Co., KGaA, Weinheim	
	P103	Gridelli et al., "Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer" The Oncologist (2007) 12:191-200	
	P104	Guan et al., "H5N1 influenza: A protean pandemic threat," Proc. Natl. Acad. Sci. USA, 25-05-2004; Vol. 101, pp. 8156-8161	
	P106	Gupta et al., "Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma" Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol. 25, No. 18S (June 20 Supplement), 2007: 6019 abstract	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	32	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P107	Gura, "Systems for identifying new drugs are often faulty." <i>Science</i> , 1997, Vol. 278, (5340), pp. 1041-1042, MEDLINE with Full text	
	P108	Hahn et al., "Sorafenib," <i>Curr. Opin. Oncol.</i> 18:615-621 (2006)	
	P108a	Hall-Jackson et al., "Paradoxical activation of Raf by a novel Raf inhibitor," <i>Chemistry & Biology</i> , 6: 559-568 (July 1999)	
	P109	Han et al., "Targeted Prodrug Design To Optimize Drug Delivery." <i>AAPS Pharmsci.</i> 2000: Vol. 2, No. 1, Article 6, 1-11	
	P110	Hanna, "Second-Line Treatment of Non-small Cell Lung Cancer: Big Targets, Small Progress; Small Targets, Big Progress?" <i>Journal of Thoracic Oncology</i> Vol. 1, No. 9, pp. 927-928 (November 2006).	
	P111	Hansch et al., "Contents," 21 pages, in: <i>Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds</i> , Pergamon Press, Oxford, Uk, 1990.	
	P113	Hanson. "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Inhibitors of p38 kinase," <i>Exp. Opin. Ther. Patents</i> , 1997, Vol. 7, Number 7, pp. 729-733	
	P114	Hardmann et al., excerpts from chapter 3. Principles of Therapeutics, in: Goodman & Gilman's <i>The Pharmacological Basis of Therapeutics</i> , 9th ed., 1996, pp. 51 and 57-58	
	P114a	Harris et al., "Soluble Tie2 and Flt1 Extracellular Domains in Serum of Patients with Renal Cancer and Response to Antiangiogenic Therapy," <i>Clin. Cancer Res.</i> 7:1992-1997 (2001)	
	P114b	Hayes et al., "Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma," <i>British Journal of Surgery</i> , 91:242-247 (Published on-line Nov. 24, 2003)	
	P115	Hegedus, L.S. "Contents," 4 pages in: <i>Transition Metals In The Synthesis Of Complex Organic Molecules</i> , University Science Books, Mill Valley, California, 1994	
	P116	Heim et al., "Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RK1) BAY 43-9006," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, Vol. 41, Number 12, pp. 616-617	
	P117	Heim et al., "The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines," <i>Anti-Cancer Drugs</i> , 2005, Vol. 16, pp. 129-136	
	P118	Herlaar et al., "p38 MAPK signalling cascades in inflammatory disease," <i>Molecular Medicine Today</i> , Vol. 5, pp. 439-447 (October 1999)	
	P118a	Herrera et al., "Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention," <i>Trends in Molecular Medicine</i> , 2002, Vol. 8, No. 4 (Suppl.), pp. S27-S31	
	P119	Higuchi T. et al., "Contents," in: <i>Prodrugs as Novel Drug Delivery Systems</i> , ACS Symposium Series 14, American Chemical Society, Washington, DC, 1975, p. vii	
	P119a	Higuchi et al., "Mitochondrial DNA determines androgen dependence in prostate cancer cell lines," <i>Oncogene</i> , 2006, Vol. 25, pp. 1437-1445	
	P120	Hilger et al., "Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006" <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 42, No. 11, pp. 648-649 (2004)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	33	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P121	Hilger et al., "ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor Bay 43-9006" International Journal of Clinical Pharmacology and Therapeutics, Vol. 40, No. 12, pp. 567-568 (2002)	
	P122	Hilger et al., "Inhibition of ERK phosphorylation and clinical outcome in patients treated with the Raf kinase inhibitor BAY 43-9006" Proc Am Soc Clin Oncol 21: 2002 (abstr 1916), 3 pages	
	P123	Hirasawa et al., "Effect of p38 Mitogen-Activated Protein Kinase on the Replication of Encephalomyocarditis Virus." Journal of Virology, 05/2003: Vol. 77, No. 10, pp. 5649-5656	
	P124	Holmlund et al., "Phase I Trial of C-raf Antisense Oligonucleotide ISIS 5132 (CGP 69846A) By 21-Day Continuous Intravenous Infusion (CIV) In Patients With Advanced Cancer," (Meeting abstract), 1998 ASCO Annual Meeting, Abstract no. 811, 2 pages	
	P125	Hotte et al., "Bay 43-9006: Early clinical data in patients with advanced solid malignancies," Current Pharmaceutical Design, 8: 2249-2253, 2002	
	P125a	Hu et al., "Soluble Vascular Endothelial Growth Factor Receptor 1, and Not Receptor 2, Is an Independent Prognostic Factor in Acute Myeloid Leukemia and Myelodysplastic Syndromes," Cancer, 100(9): 1884-1891 (Published on-line March 29, 2004)	
	P126	Hubbard, "Oncogenic Mutations in B-Raf: Some Losses Yield Gains," Cell Volume 116, Issue 6, 764-766 (2004)	
	P126a	Hyodo et al., "Clinical Significance of Plasma Vascular Endothelial Growth Factor in Gastrointestinal Cancer," European Journal of Cancer, 34(13): 2041-2045 (1998)	
	P127	Ihle et al., "Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling," Molecular Cancer Therapy, Vol. 3, No. 7, 2004, pp. 763-772	
	P127a	Ishigami et al., "Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer," British Journal of Cancer, 78(10): 1379-1384 (1998)	
	P127b	Jacobsen et al., "Vascular Endothelial Growth Factor as Prognostic Factor in Renal Cell Carcinoma," Journal of Urology, 163(1): 343-347 (Jan. 2000)	
	P127c	Jacobsen et al., "Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma," European Journal of Cancer Prevention, 2002, 11(3) pp. 245-252	
	P128	Jain et al., "Randomized Discontinuation Trial of Sorafenib (BAY 43-9006)," Cancer Biology & Therapy, Vol. 5, Issue 10, pp. 1270-1272 (2006).	
	P129	Jeffcoat et al., "The Metabolism and Toxicity of Halogenated Carbanilides," Drug Metabolism and Disposition, Vol. 5, Number 2, pp. 157-166 (1977)	
	P129a	Jimeno et al., "Analysis of Biologic Surrogate Markers from a Children's Oncology Group Phase I Trial of Gefitinib in Pediatric Patients with Solid Tumors," Pediatr. Blood Cancer, 49(3): 352-357 (2007)	
	P130	Jin et al., "Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells." British Journal Of Cancer, Vol. 91, 2004, pp. 1808-1812	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	34	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P131	Johnson et al., "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials," British Journal of Cancer, 2001, Vol. 84, No. 10, pp. 1424-1431	
	P132	Johnston, D, et al., "Elevation of the Epidermal Growth Factor Receptor and Dependent Signaling in Human Papillomavirus-infected Laryngeal Papillomas," Cancer Research, 1999: Vol. 59, pp. 968-974	
	P132b	Jungmayr, P., "Aktueller Stand der Krebstherapie," Deutsche Apotheker Zeitung, Sept 30, 2004, Auflage ca. 36.000	
	P133	Kapoun et al., "TGFβR1 kinase activity, but not p38 activation is required for TGFβR1-induced myofibroblast differentiation and pro-fibrotic gene expression," Molecular Pharmacology Fast Forward, abstract, 2006, www.molpharmaspjournals.org, 2 pages	
	P133a	Karayiannakis et al., "Circulating VEGF Levels in the Serum of Gastric Cancer Patients," Annals of Surgery, 236(1): 37-42 (July 2002)	
	P133b	Karayiannakis et al., "Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery," Surgery, 131(5): 548-555 (May 2002)	
	P133c	Karp et al., "Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-β-D Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab," Clinical Cancer Research, 10: 3577-3585 (June 1, 2004)	
	P134	Katritzky et al., "1.18. Azetidines, Azetines, and Azetes: Monocyclic" pp. 507-508 in: Comprehensive Heterocyclic Chemistry II, A Review of the Literature 1982-1995: The Structure, Reactions, Synthesis, and Uses of Heterocyclic Compounds. Pergamon Press, Oxford, UK, 1996	
	P135	Katritzky, Alan R., Tables of Content, in: Comprehensive Organic Functional Group Transformations. Pergamon Press, Oxford, UK, 1995, 25 pages	
	P136	Katritzky et al., "Contents," 2 pages, in: Comprehensive Heterocyclic Chemistry, The Structure, Reactions, Synthesis, and Uses of Heterocyclic Compounds. Pergamon Press, Oxford, UK, 1984	
	P137	Keller et al., "The role of Raf kinase inhibitor protein (RKIP) in health and disease," Biochemical Pharmacology 68; pp. 1049-1053 (2004)	
	P139	Kempler et al., "Synthese potentieller Pflanzenschutz- und Schädlingsbekämpfungsmittel aus substituierten Anilinen," Pädagogische Hochschule, Eingegangen am 1.7.1982, Vol. 27, Issue 1, 101-120 (1983)	abs
	P140	Kessler et al., "Use of the DNA Flow-Thru Chip, a Three-Dimensional Biochip, for Typing and Subtyping of Influenza Viruses," Journal of Clinical Microbiology, 05-2004; Vol. 42, pp. 2173-2185	
	P141	Khire et al., "Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent," Bioorg. Med. Chem. Lett., 2004, Vol. 14, pp. 783-786	
	P141a	Kido, Y., "Vascular Endothelial Growth Factor (VEGF) Serum Concentration Changes during Chemotherapy in Patients with Lung Cancer," Kurume Medical Journal, 48(1): 43-47 (2001)	
	P142	Klemm et al., "Chemistry of Thienopyridines. XXXVII. Syntheses in the Cyclopenta, Cyclohexa-, and Cycloheptathieno[2,3-b]pyridine Series. Three Analogs of 9-Amino-1,2,3,4-tetrahydroacridine [1]," J. Heterocyclic Chem., 27, 1990, pp.1537-1541	
	P143	van Muijlwijk-Koezen et al., "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A ₃ Receptor," J. Med. Chem. 2000, 43, pp. 2227-2238	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	35	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P144	Kolch et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Nature, Vol. 349, January 31, 1991, pp. 426-428	
	P145	Kolch et al., "The role of Raf kinases in malignant transformation" Expert reviews in molecular medicine (April 25, 2002) ISSN: 1462-3994 © Cambridge University Press, 18 pages	
	P145a	Konecny et al., "Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients," Clinical Cancer Research, 10: 1706-1716 (March 1, 2004)	
	P145b	Korfee et al., "New targeted treatments in lung cancer-overview of clinical trials," Lung Cancer, 45 (Suppl. 2): S199-S208 (2004)	
	P145c	Kraft et al., "Vascular Endothelial Growth Factor in the Sera and Effusions of Patients with Malignant and Nonmalignant Disease," Cancer, 85(1): 178-187 (Jan 1, 1999)	
	P146	Kubo et al., "Herbicidal Activity of 1,3,4-Thiadiazole Derivatives," J. Agr. Food Chem. (1970), 18(1), pp. 60-65	
	P147	Kubo et al., "Synthesis and structure-activity relationship of quinazoline-urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors," Proceedings of the American Association of Cancer Res., 2002, Vol. 43, p. 182, abstract no. 913	
	P148	Kuefer et al., "Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway," Der Urologe, 2006, Vol. 45, No. 3, pp. 328, 330-335	abs
	P149	Kumar et al., "Drugs targeted against protein kinases" Expert Opin. Emerging Drugs 6(2):303-315 (2001)	
	P150	Kupsch et al., "Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer," Clinical Colorectal Cancer, Cancer Information Group Journal, Vol. 5 Issue 3, pp. 188-196, abstract (September 2005)	
	P151	Kurik et al., "Optical Properties of Segmented Oligourethane with Azomethine Terminal Fragments," Polymer Science, series B, 1996, Vol. 38 pp. 2038-2041	abs
	P152	Kyriakis et al., "Raf-1 activates MAP kinase-kinase" Nature, 358, 6385, pp. 417-421 (July 30, 1992).	
	P152a	Laack et al., "Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer," Annals of Oncology, 13(10): 1550-1557 (Oct 2002)	
	P153	Dal Lago et al., "Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors" The Oncologist, Vol. 13, No. 8, pp. 845-858 (Aug 11, 2008)	
	P153a	Lau et al., "Abrogation of c-Raf expression induces apoptosis in tumor cells," Oncogene 16, 1899-1902 (1998)	
	P154	Lee et al., "BAY-43-9006 Bayer/Onyx." Current Opinion in Investigational Drugs, 2003, Vol. 4, Number 6, pp. 757-763	
	P155	Lee et al., "Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," Annals N.Y. Academy of Science, 1993, Vol. 696, pp. 149-170	
	P156	Lee et al.: "FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation," Carcinogenesis, Vol. 25, No. 12, 2004, pp. 2397-2405	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	36	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹⁶
	P156a	Lee et al., "Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients," European Journal of Cancer, 36(6): 748-753 (April 2000)	
	P156b	Lee and Heymach, "Emerging Antiangiogenic Agents in Lung Cancer," Clinical Lung Cancer, 7(5): 304-308 (March 2006)	
	P156c	Legros et al., "Imatinib mesylate (ST1571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia," Blood, 104(2): 495-501 (Prepublished on-line Feb 19, 2004)	
	P157	Lemoine, "Overview of <i>ras</i> oncogenes and their clinical potential," Chapter 10, In: Mutant Oncogenes: Targets for Therapy? (eds. Lemoine NR & Epenetos A), Chapman & Hall, London, pp. 85-91	
	P158	Lepage et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem., Vol. 27, 1992, pp. 581-593	
	P159	Leuner et al., "Improving drug solubility for oral delivery using solid dispersions," European Journal of Pharmaceutics and Biopharmaceutics, 50, 2000, pp. 47-60	
	P159a	Liang et al., "Differential Expression of VEGF and Its Receptors in the Primary Cells of Various Risk Classified Acute Lymphoblastic Leukemia Patients," Blood 104: Abstract 4446 (2004)	
	P159b	Li et al. "Correlation of Serum VEGF Levels with Clinical Stage, Therapy Efficacy, Tumor Metastasis and Patient Survival in Ovarian Cancer," Anticancer Research, 24: 1973-1980 (2004)	
	P160	Lin, "Synthesis of 1-(2-Pyridine-1-oxide)-2-(1-Methyl-2-Pyridinium)-Ethane Chloride," OPPI Briefs, Vol. 23, No.1, 1991, pp. 114-115	
	P160a	Linderholm et al., "Correlation of Vascular Endothelial Growth Factor Content with Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment," Journal of Clinical Oncology, 18(7): 1423-1431 (April 2000)	
	P160b	Linderholm et al., "p53 and Vascular-Endothelial-Growth-Factor (VEGF) Expression Predicts Outcome in 833 Patients with Primary Breast Carcinoma," Int. J. Cancer (Pred. Oncol.): 89(1): 51-62 (2000)	
	P160c	Lissoni et al., "Anti-angiogenic activity of melatonin in advanced cancer patients," Neuroendocrinology Letters, 2001, 22:45-47	
	P160d	Lissoni et al., "Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer," International Journal of Biological Markers, 15(4): 308-311 (Oct. 1, 2000)	
	P160e	Lissoni et al., "Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1," Journal of Biological Regulators and Homeostatic Agents, 15(2): 140-144 (April 2001)	
	P160f	Lissoni et al., "Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer," International Journal of Biological Markers, 18(2): 152-155 (2003)	
	P160g	Llovet et al., "Molecular Targeted Therapies in Hepatocellular Carcinoma," Hepatology, Vol. 48, No. 4, pp. 1312-1327, 2008	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	37	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P160h	Lockhart et al., "Phase I/Pilot Study of SU5416 (Semaxinib) in Combination With Irinotecan/Bolus 5-FU/LV (IFL) in Patients With Metastatic Colorectal Cancer," American Journal of Clinical Oncology, 29(2):109-115 (April 2006)	
	P161	Lorigan et al., "Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients" ASCO 2006 DTIC abstract, 2 pages (January 11, 2006)	
	P162	Lowinger et al., "Design and Discovery of Small Molecules Targeting Raf-1 Kinase," Current Pharmaceutical Design, 2002, Vol. 8, pp. 2269-2278	
	P163	Lowinger et al., "Discovery of novel class of potent Raf kinase inhibitors: structure activity relationships," Clinical Cancer Research, November 2000, Vol. 6 (Suppl.), p. 4533s, abstract no. 335	
	P163a	Lowy et al., "Function and Regulation of RAS" Annual Review of Biochemistry, Vol. 62, pp. 851-891, 1993	
	P164	Ludwig et al., "MEK inhibition impairs influenza B virus propagation without emergence of resistant variants," PLoS Letters, 2004, Vol. 561, pp. 37-43	
	P165	Luo et al., "Enhancement of radiation effects by pXIG-mENDO in a lung carcinoma model," Int. J. Radiation Oncology Biol. Phys., 2005, Vol. 63, No. 2, pp. 553-564	
	P166	Lyons et al., "Discovery of a novel Raf kinase inhibitor," Endocrine-Related Cancer, 2001, Vol. 8, pp. 219-225	
	P167	Madwed et al., "Pharmacological evaluation of BIRB 796, a selective inhibitor of p38 MAP kinase (MAPK), in animal models of endotoxic shock, inflammation and arthritis," Inflammation Res., 50:S184, abstract no. W22/03, 2001	
	P168	Magnuson et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, Vol. 5, 1994, pp. 247-253	
	P168a	Manenti et al., "Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy," Molecular Cancer Therapeutics, 4(5): 715-725 (May 2005)	
	P169	Mannová et al., "Activation of the N-Ras-P13K-Akt-mTOR Pathway by Hepatitis C Virus: Control of Cell Survival and Viral Replication," Journal of Virology, July 2005, Vol. 79, No.14, pp. 8742-8749	
	P170	Markgraf et al., "Strained Heterocyclic Systems. 19. 1-Azatriptycene and Derivatives," Tetrahedron, Vol. 47, No. 2, 1991, pp. 183-188	
	P171	Marshall, "MAP kinase kinase kinase, MAP kinase kinase, and MAP kinase," Curr. Opin. Genet. Dev. 4: 82-89, 1994	
	P171a	Marx, J., "Why a New Cancer Drug Works Well, In Some Patients," Science, Vol. 304, pp. 658-659, 2004	
	P172	McGoon et al., "Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension," CHEST, 2004: 126, pp. 14S-34S	
	P172a	Medinger et al., "Hemmung der Tumorangienese Neue Therapieoptionen in der Onkologie," Med Welt, 2006, 57, pp. 437-441	abs
	P172b	Med Report Deutschland, "Sorafenib zur Therapie des fortgeschrittenen Nierenzellkarzinoms zugelassen," (2006), 1 page	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	38	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P173	Meuillet et al., "In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316," <i>Oncology Research</i> , Vol. 14, 2004, pp. 513-527	
	P174	Michaelis, "Phenylharnstoff des 1-Phenyl-3-methyl-5-aminopyrazols," <i>Justus Liebigs Ann. Chem. (JLACBF)</i> 397, 1913, p. 143	
	P174a	Milanini et al., "p42/p44 MAP Kinase Module Plays a Key Role in the Transcriptional Regulation of the Vascular Endothelial Growth Factor Gene in Fibroblasts," <i>Journal of Biological Chemistry</i> , 273(29): 18165-18172 (July 17, 1998)	
	P175	Milano et al., "New molecular targeted therapies in thyroid cancer" <i>Anti-Cancer Drugs</i> (2006) © Lippincott Williams & Wilkins., Vol. 17:869-879	
	P175a	Mills et al., "The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer," <i>Clinical Cancer Research</i> , 10: 4998-5003 (August 1, 2004)	
	P175b	Milojokovic et al., "Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate," <i>Blood</i> , 104 Abstract 1999 (2004)	
	P175c	Minna et al., "A Bull's Eye For Targeted Lung Cancer Therapy," <i>Science</i> , Vol. 304, pp. 1458-1460, 2004	
	P176	Mita et al., "The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer," <i>Cancer Biology & Therapy</i> 2:4 Suppl. 1, S169-S177 (July/August 2003)	
	P177	Moelling et al., "Signal Transduction as Target of Gene Therapy," <i>Institute of Medical Virology, University of Zürich, Recent Results in Cancer Research</i> , Vol. 142, pp. 63-71 (1996)	
	P178	Molhoek et al., "Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY 43-9006 and mTOR inhibitor rapamycin," <i>Journal of Translational Medicine</i> (2005) 3: 39, pp.1-11	
	P179	Monia, "First-and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase," (1997) <i>Oligonucleotides as therapeutic agents</i> Wiley, Chichester (Ciba Foundation Symposium 209) pp. 107-123	
	P180	Monia et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," <i>Nature Medicine</i> , Vol. 2, No. 6, June 1996, pp. 668-675	
	P180a	Monia et al., "Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports and antisense mechanism of action <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci USA</i> , Vol. 93, 15481-15484 (Dec. 1996)	
	P180b	Morabito et al., Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors I <i>Clinical Trials: Current Status and Future Directions</i> , The Oncologist, 11: 753-764 (2006)	
	P181	Mori et al., "Differential activation of the c-Jun N-terminal kinase/stress-activated protein kinase and p38 mitogen-activated protein kinase signal transduction pathways in the mouse brain upon infection with neurovirulent influenza A virus," <i>Journal of General Virology</i> , 2003, 84, pp. 2401-2408	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	39	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7 ⁶
	P182	Moore et al., "Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors," Annals of Oncology, 2005, Vol. 16, pp.1688-1694	
	P183	Motzer et al., "Survival And Prognostic Stratification Of 670 Patients With Advanced Renal Cell Carcinoma", J. Clin. Oncol., 17(8):pp. 2530-2540 (1999).	
	P184	Mross et al., "Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RK1) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors," International Journal of Clinical Pharmacology and Therapeutics, 2003, Vol. 41, Number 12, pp. 618-619	
	P185	Mross et al., "Results from an <i>in vitro</i> and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib" European Journal of Cancer 43, pp. 55-63 (2007).	
	P186	Murata et al., "Facile Synthesis of New Pyrrolo[3,4- <i>d</i>]pyrimidine-2,4-diones," Chemical and Pharmaceutical Bulletin, Vol. 22, Number 5, 1974, pp. 1212-1213	
	P187	Murphy et al., "BAY 43-9006 controls tumor growth through inhibition of vascular development," 96 th Annual Meeting, Anaheim/Orange County, CA, April 16-20, 2005, abstract no. 2985	
	P188	Muthumani et al., "Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor," AIDS, Lippincott Williams & Wilkins, 2004: Vol. 18, pp. 739-748.	
	P189	National Cancer Institute, "Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma", 7 pages, NCT00110019, clinicaltrials.gov. (2005)	
	P190	National Cancer Institute, "Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer," 5 pages, NCT00096226, (2005)	
	P191	National Cancer Institute, "Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer," 5 pages, NCT00096200, (2005)	
	P192	National Cancer Institute, Clinical Trials (PDQ®), "Phase II Randomized Study of ISIS 5132 or ISIS 3521 in Women with Previously Treated Metastatic Breast Cancer," 3 pages, www.cancer.gov website (1998).	
	P193	National Cancer Institute, Clinical Trials (PDQ®), "Phase II Randomized Study of ISIS 3521 and ISIS 5132 for Locally Advanced or Metastatic Colorectal Cancer," 3 pages, www.cancer.gov website (1998).	
	P194	National Cancer Institute, Clinical Trials (PDQ®), "Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Hormone Refractory Prostate Cancer," 3 pages, www.cancer.gov website (1998).	
	P195	National Cancer Institute, Clinical Trials (PDQ®), "Phase II Study of ISIS 5132 in Patients with Advanced Pancreatic Cancer," 3 pages, www.cancer.gov website (1999).	
	P196	National Institutes Of Health Clinical Center, "BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer", 4 pages, NCT00098254, clinicaltrials.gov (2005).	
	P197	Naumann et al., "Raf protein serine/threonine kinases" in: Protein Phosphorylation, VCH Verlagsgesellschaft mbH Chapter 7, pp. 203-236 (1996).	
	P198	Naumann et al., "The Role of Raf Kinases in Development and Growth of Tumors" Recent Results in Cancer Research, Vol. 143, pp. 237-244 (1997).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	40	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P199	Nemunaitis et al., "Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients with Advanced Cancer" Journal of Clinical Oncology. Vol. 17, No. 11, pp 3586-3595 (November 1999).	
	P199a	Neufeld et al., "Vascular endothelial growth factor (VEGF) and its receptors, "The FASEB Journal, 13: 9-22 (Jan. 1999)	
	P200	"Nexavar Receives FDA Fast Track Designation for Skin Cancer" 4 pages, (July 21, 2006) http://www.medicalnewstoday.com/articles/47793.php (last visited on 6/16/2008).	
	P201	Nicholson, K. M. et al.: "The protein kinase B/Akt signalling pathway in human malignancy," Cellular Signalling 14, 2004, pp. 381-395	
	P202	Nickel et al., "Carboxylic acid analogues of suramin, potential filaricides," Indian Journal of Chemistry, February 1991, Vol. 30B, pp. 182-187	
	P202a	Nilsson et al., "Vascular Endothelial Growth Factor (VEGF) Pathway," Journal of Thoracic Oncology, 1(8): 768-770 (Oct. 2006)	
	P202b	Noble et al., "Protein Kinase Inhibitors: Insights into Drug Design From Structure," Science, (2004), Vol. 303, pp 1800-1805	
	P203	O'Dwyer et al., "c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A)," Clinical Cancer Research Vol. 5, pp. 3977-3982 (December 1999)	
	P204	Oka et al., "Constitutive Activation of Mitogen-activated Protein (MAP) Kinases in Human Renal Cell Carcinoma." Cancer Research 55, pp. 4182-4187, (September 15, 1995)	
	P205	Gollob et al., "Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma." European Journal of Cancer, 2005, Vol. 3, No. 2, pp. 226-227, abstract no. 795	
	P205a	Osella-Abate et al., "VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course," Melanoma Research, 12: 325-334 (Aug. 2002)	
	P205b	Oza et al., "Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND 116)," PubMed Abstract 12694666, Gynecol. Oncol. 2003 Apr; 89(1):129-133	
	P206	Ozols, "New Developments With Carboplatin in the Treatment of Ovarian Cancer," <i>Seminars in Oncology</i> , Vol. 19, Number 1, Supplement 2, February 1992, pp. 85-89	
	P207	Panka et al., "BAY 43-9006 induces apoptosis in melanoma cell lines," 96 th Annual Meeting, Anaheim/Orange County, CA, April 16-20, 2005, abstract no. 5328	
	P208	Panteva et al., "Hepatitis viruses and the MAPK pathway: is this a survival strategy?" <i>Virus Research</i> , 2003, Vol 92: 131-140.	
	P209	Paquette, Table of Contents for The Encyclopedia of Reagents for Organic Synthesis, John Wiley, New York, 1994 Table of Contents	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	41	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹ 6
	P210	Pavlović-Lazetić et al., "Bioinformatics analysis of SARS coronavirus genome polymorphism," 25-05-2004, BMC Bioinformatics, Vol. 5:65, 14 pages	
	P210a	Pederson et al., "Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma," Ann. Hematol., 84:510-516 (2005)	
	P210b	Peters, H.D., "Sorafenib bei soliden Tumoren," Focus Onkologie, 2007, Auflage 12000, 6 pages	
	P211	Robert et al., "Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma," European Journal of Cancer, 2005, Vol. 3, No. 2, p. 254, Abstract 883	
	P212	Hu et al., "Soluble Vascular Endothelial Growth Factor Receptor 1, and Not Receptor 2, Is an Independent Prognostic Factor in Acute Myeloid Leukemia and Myelodysplastic Syndromes," Cancer 2004, Vol. 100, no. 9, pp. 1884-1891	
	P213	Raez et al., "New developments in chemotherapy for advanced non-small cell lung cancer," Current Opin. Oncol., Vol. 18, 2006, pp. 156-161	
	P214	Rahmani et al., "Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation," J. Biol. Chem. 280(42):35217-35227 (2005)	
	P215	Rak et al., "Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth," Journal of Investigative Dermatology Symposium Proceedings (2000) 5, 24-33	
	P216	Rak et al., "Oncogenes and Tumor Angiogenesis: Differential Modes of Vascular Endothelial Growth Factor Up-Regulation in <i>ras</i> -transformed Epithelial Cells and Fibroblasts," Cancer Research 60, pp. 490-498, (January 15, 2000)	
	P217	Rak et al., "Oncogenes as inducers of tumor angiogenesis," Cancer and Metastasis Reviews 14: 263-277, 1995	
	P218	Sturm-Ramirez et al., "Reemerging H5N1 Influenza Viruses in Hong Kong in 2002 Are Highly Pathogenic to Ducks," Journal of Virology, 2004-05, 78(9):4892-4901	
	P219	Raposo et al., "Catalysis of Nucleophilic Addition of Pyrrolidine to 2-(5H)-Furanone through Chromenone Cleft-Type Receptors," Tetrahedron Letters Vol. 37, No. 38, pp. 6947-6950, 1996	
	P220	Ratain et al., "Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients with Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology Vol. 24 No. 16, pp. 2505-2512 (June 1, 2006)	
	P221	Ravi et al., "Activated Raf-1 Causes Growth Arrest in Human Small Cell Lung Cancer Cells," J. Clin. Invest., Vol. 101, no. 1, pp. 153-159 (1998)	
	P222	Reddy et al., "Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma," Clin. Genitourin. Cancer 4:246-248 (2006) abstract	
	P223	Redman et al., "p38 Kinase Inhibitors for the Treatment of Arthritis and Osteoporosis: Thienyl, Furyl, and Pyrrolyl Ureas," Bioorganic & Medicinal Chemistry Letters 11 (2001) 9-12	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	42	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹⁻⁶
	P224	Regan et al., "Pyrazole Urea-Based Inhibitors of p38 MAP kinase: From Lead Compound to Clinical Candidate." J. Med. Chem. 45:2994-3008, 2002	
	P225	Richly et al., "A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors." International Journal of Clinical Pharmacology and Therapeutics, 2003, Vol. 41, Number 12, pp. 620-621	
	P226	Richly et al., "Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors," Annals of Oncology, 2006, 17, pp. 866-873	
	P227	Richly et al., "Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer," International Journal of Clinical Pharmacology and Therapeutics, 2004, Vol. 42, Number 11, pp. 650-651	
	P228	Ridley et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase, Regulation of Prostaglandin H Synthase-2, Metalloproteinases, and IL-6 at Different Levels," The American Association of Immunologists, 1997, J. Immunol. Vol. 158, pp. 3165-3173	
	P228a	Rini and Small, "Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma," Journal of Clinical Oncology, 23(5): 1028-1043 (Feb. 10, 2005)	
	P228b	Robak et al., "Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus." Mediators of Inflammation 12(5):293-298 (October 2003)	
	P229	Robertson et al. "HIV-1 Nomenclature Proposal," Science, April 7, 2000, pp. 55-57, Vol. 288	
	P230	Robinson et al., "Enhanced Radiosensitization with Gemcitabine in Mismatch Repair-Deficient HCT116 Cells," Cancer Research 63, 6935-6941 (October 15, 2003)	
	P231	Robke et al., "Conversion of Aminopyridines into N-Oxides by Caro's Acid Anion (Peroxymonosulfate)," J. Chem. Research (S), 1993, pp. 412-413	
	P232	Roche, E. B., "Structural Aspects of Selective Distribution," Chapter 3, in: Design of Biopharmaceutical Properties Through Prodrugs and Analogs, American Pharmaceutical Association, Washington, D.C., 1977, pp. 27-46	
	P232a	Rodriguez et al., "A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor ₁₆₅ in human plasma," Journal of Immunological Methods, 219(1-2): 45-55 (Oct. 1998)	
	P233	Roman et al., "Human Papillomaviruses: Are We Ready to Type?" Clinical Microbiology Reviews. 04-1989: Vol. 2, pp.166-190	
	P234	Rowinsky et al., "Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study," Journal of Clinical Oncology, Vol. 9, Number 9, September 1991, pp. 1692-1703	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	43	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹ 6
	P235	Rowinsky et al., "Taxol: The First of the Taxanes, an Important New Class of Antitumor Agents," <i>Seminars in Oncology</i> , Vol. 19, Number 6, December 1992, pp. 646-662	
	P236	Rubin, Lewis J., "Primary Pulmonary Hypertension," <i>New England Journal of Medicine</i> , Vol. 336, No 2, pp. 111-117 (1997)	
	P237	Rudin et al., "Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of <i>c-ras</i> -1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer" <i>Clinical Cancer Research</i> Vol. 7, pp. 1214-1220 (May 2001).	
	P238	Russo et al., "Sintesi Di Derivati 2,6-Sostituiti Del 5H-1,3,4-Tiadiazolo[3,2-a]-s-Triazina-5,7-Dione," <i>Il Farmaco</i> , Ed.Sci. (1978), 33(12), 972-983	
	P238a	Ryden et al., "Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer," <i>Breast Cancer Research and Treatment</i> , 82(3):147-154 (Dec. 2003)	
	P239	Salvatore et al., "BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma," <i>Clin. Cancer Res.</i> pp. 1623-1629; 12(5) (March 1, 2006).	
	P240	Sarkar et al., "Indole-3-Carbinol And Prostate Cancer," <i>Journal of Nutrition</i> 134, 2004, pp. 3493S-3498S	
	P241	Serajuddin, "Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises Subsequent Problems, and Recent Breakthroughs," <i>Journal of Pharmaceutical Sciences</i> Vol 88, No. 10, pp. 1058-1066 (October 1999)	
	P241a	Shaked et al., "Cellular and Molecular Surrogate Markers to Monitor Targeted and Non-Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose," <i>Current Cancer Drug Targets</i> , 5: 551-559 (Nov. 2005)	
	P242	Shelton et al., "Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells," <i>Oncogene</i> , Vol. 22, No. 16, 04/2003; pp. 2478-2492	
	P243	Shi et al., "Constitutive and Inducible Interleukin 8 Expression by Hypoxia and Acidosis Renders Human Pancreatic Cancer Cells More Tumorigenic and Metastatic," <i>Clinical Cancer Research</i> , 1999, Vol. 5, pp. 3711-3721	
	P243a	Shimanuki et al., "Role of Serum Vascular Endothelial Growth Factor in the Prediction of Angiogenesis and Prognosis for Non-small Cell Lung Cancer," <i>Lung</i> , 183: 29-42 (2005)	
	P244	Simone, Joseph, V., "Part XIV. Oncology," in: <i>Cecil Textbook of Medicine</i> , 20th Edition, Vol. 1, 2-3-1997. W.B. Saunders Company, pp. 1004-1010	
	P245	Sinkula et al., "Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs," <i>Journal of Pharmaceutical Sciences</i> , Vol. 64, No. 2, February 1975, pp. 181-210	
	P246	Siu et al., "Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors," Abstract no. 828, <i>Proc. Am. Soc. Clin. Oncol.</i> , 2003, Vol. 22, p. 207	
	P247	Siu et al., "Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer," <i>Clin. Cancer Res.</i> 12(1):144-151 (2006)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	44	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P248	Smith et al., "Discovery of Heterocyclic Ureas as a New Class of Raf Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry Approach." Bioorganic & Medicinal Chemistry Letters, 2001, Vol. 11, pp. 2775-2778	
	P249	Smith et al., (Abstract) "Recent Advances in the Research and Development of RAF Kinase Inhibitors," Current Topics in Medicinal Chemistry 6(11):1071-1089 (2006)	
	P250	Smyth, R.M. et al., "Anchimeric Assistance in the Specific Acid-catalysed Hydration of Benzonitriles" J. Chem. Soc. Perkin Trans. 2 1993 pp, 2171-2174	
	P251	Song, Huai-Dong et al., "Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human." Proc. Natl. Acad. Sci. USA 102(7):2430-2435 (2005)	
	P252	Sorbara et al., "BAY-43-9006," Drugs of the Future, 2002, Vol. 27, Number 12, pp. 1141-1147	
	P253	van Spronsen et al., "Novel treatment strategies in clear-cell metastatic renal cell carcinoma," Anti-Cancer Drugs, 2005, Vol. 16, pp. 709-717	
	P253a	Stadler et al., "A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer," Clinical Cancer Research, 10: 3365-3370 (May 15, 2004)	
	P254	Stahl et al., "Deregulated Akt3 Activity Promotes Development of Malignant Melanoma." Cancer Research, Vol. 64, No. 19; 10/2004; pp. 7002-7010	
	P255	Stavchansky et al., "Evaluation of the Bioavailability of a Solid Dispersion of Phenytoin in Polyethylene Glycol 6000 and a Commercial Phenytoin Sodium Capsule in the Dog," Journal of Pharmaceutical Sciences, Vol. 73, No. 6, June 1984, pp. 733-736	
	P256	Krontiris, "Chapter 71. Molecular and Cellular Biology of Cancer," and Capizzi, "Chapter 72. Principles of Treatment of Cancer," in: Internal Medicine, 4th Edition. Stein, Jay H., MD, Ed., Mosby, 1994, pp. 699-715	
	P257	Sternberg et al., "Conspiracy Theory: RAS and RAF Do Not Act Alone" Cell, Vol. 95, pp. 447-450 (November 13, 1998).	
	P258	Stella et al., "Prodrugs and Site-Specific Drug Delivery," Journal of Medicinal Chemistry, Vol. 23, No. 12, December 1980, pp. 1275-1282	
	P259	Stella et al., "Prodrugs as therapeutics," Exp. Opin. Ther. Patents 14(3): 277-280 (2004)	
	P260	Stella et al., "Prodrugs. Do They Have Advantages in Clinical Practice?" Drugs, Vol. 29, 1985, pp. 455-473	
	P260a	Stevenson et al., "Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)," The Journal of Clinical Oncology, Vol. 17, No7: pp. 2227-2236 (July 1999)	
	P261	Stöckl et al., "Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression," Oncogene, Nature Publishing Group, 2003: Vol. 22, pp. 2604-2610	
	P262	Stokoe et al., "Activation of c-Raf-1 by Ras and Src through different mechanisms: activation <i>in vivo</i> and <i>in vitro</i> ," The Embo Journal, Vol. 16 No. 9 pp. 2384-2396 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	45	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P263	Storm et al., "raf Oncogenes in Carcinogenesis" Critical Reviews in Oncogenesis, Vol. 2, Issue 1, pp. 1-8 (1990)	
	P263a	Strumberg, D., "Preclinical and Clinical Development of the Oral Multikinase Inhibitor Sorafenib in Cancer Treatment," Drugs of Today, 41(12): 773-784 (2005)	
	P264	Strumberg et al., "Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors," Journal of Clinical Oncology, February 10, 2005, Vol 23, Number 5, pp. 965-972	
	P265	Strumberg et al., "Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of the Raf Kinase Inhibitor BAY 43-9006 in Patients with Locally Advanced or Metastatic Cancer," Proc. Am. Soc. Clin. Oncol. 20: 2001 (abstr 330)	
	P266	Strumberg et al., "Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors," International Journal of Clinical Pharmacology and Therapeutics, 2002, Vol 40, Number 12, pp. 580-581	
	P266a	Strumberg et al., "Sorafenib Neue Therapieoption in der Onkologie," Krankenhauspharmazie, 2007, Vol. 28, pp. 93-97, pages 1/5, 2/5, 3/5 and 4/5	
	P267	Suzuki et al., "The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF- α - or IL-1 β -stimulated rheumatoid synovial fibroblasts," FEBS Letters (2000), Vol. 465, pp. 23-27	
	P268	Swarbrick et al., "Contents," pp. xvii-xviii in: Encyclopedia of Pharmaceutical Technology," 2nd Edition, Marcel Dekker, Inc. 2002	
	P269	Swart, Guido W.M., "International Melanoma Research Congress - Foundation for Melanoma Research," IDRUGS: The Investigational Drugs Journal, 08/2003; Vol. 6, no. 8, pp. 752-754	
	P270	Tabellini et al., "Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway," British Journal Of Haematology, 126, 2004, pp. 574-582	
	P271	Takimoto et al., "Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials," Cancer Chemotherapy and Pharmacology (2008) 61:535-548	
	P272	Tamm et al., "Hypoxia-Induced Interleukin-6 and Interleukin-8 Production Is Mediated by Platelet Activation Factor and Platelet-Derived Factor in Primary Human Lung Cells," Am. J. Respir. Cell Mol. Biol. Vol. 19, pp. 653-661, (1998)	
	P273	Tanaka et al., "Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma," Int. J. Clin. Oncol. (2006) 11:82-89 (2006)	
	P274	Tang et al., "Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor," Am. J. Physiol. Lung Cell. Mol. Physiol. 287:L344-L351 (2004)	
	P275	Tarzia et al., "Synthesis and anti-inflammatory properties of some pyrrolo(1H,3H) [3,4-d]pyrimidin-2-ones and pyrrolo=(1H,6H)[3,4-d]pyrimidin-2-ones," Chemical Abstracts, Vol. 91, 1979, 91:74558p	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	46	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P275a	Teknos et al., "Elevated Serum Vascular Endothelial Growth Factor and Decreased Survival in Advanced Laryngeal Carcinoma," Head & Neck, 24: 1004-1011 (November 2002)	
	P276	Thaimattam et al., "3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies," <i>Bioorganic & Medicinal Chemistry</i> , 2004, Vol. 12, pp. 6415-6425	
	P277	Thelen et al., "VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma" Int. J. Cancer 122, 2471-2481 (2008) © 2008 Wiley-Liss, Inc.	
	P278	Thompson et al., "Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery." Curr. Opin. Pharmacol., August 2005, Vol. 5, Number 4, pp. 350-356	
	P279	Tong et al., "Pharmacodynamic Monitoring of BAY 43-9006 (Sorafenib) in Phase I Clinical Trials Involving Solid Tumor and AML/MDS Patients, Using Flow Cytometry to Monitor Activation of the ERK Pathway in Peripheral Blood Cells," Cytometry Part B (Clinical Cytometry) 70B: 107-114 (2006)	
	P280	Trost et al., "Contents," Vols. 1-9, 36 pages in: Comprehensive Organic Synthesis: Selectivity, Strategy & Efficiency in Modern Organic Chemistry, Pergamon Press, Oxford, UK, 1991.	
	P281	Gupta-Abramson et al., "Phase II Trial of Sorafenib in Advanced Thyroid Cancer" Journal of Clinical Oncology Vol. 26, No. 29, pp. 4714-4719 (October 10, 2008).	
	P282	Veronese et al., "Mechanisms of Hypertension Associated with BAY 43-9006," Journal of Clinical Oncology, 2006, Vol. 24, No. 9, pp. 1363-1369	
	P283	Vivanco et al., "The Phosphatidylinositol 3-Kinase-AKT Pathway in Human Cancer," Nature Reviews Cancer, Vol. 2, July 2002, pp. 489-501	
	P284	Vlahos et al., "A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)," <i>The Journal of Biological Chemistry</i> , Vol. 269, No.7, 1994, pp. 5241-5248	
	P284a	Wakelee et al., "Targeting Angiogenesis with Vascular Endothelial Growth Factor Receptor Small-Molecular Inhibitors: Novel Agents with Potential in Lung Cancer," <i>Clinical Lung Cancer</i> , 7(Suppl 1): S31-S38 (Sept 2005)	
	P285	Wald et al., "Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus," <i>Eur. J. Immunol.</i> , Vol. 34, p. 1164-1174 (2004)	
	P286	Wan et al., "Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF," <i>Cell</i> , March 19, 2004, Vol. 116, pp. 855-867	
	P287	Weekly Epidemiological Record, "Influenza," World Health Organization, 04-1999; Vol. 14, pp. 111-112.	
	P288	Wermuth, C. G., "Designing Prodrugs and Bioprecursors II: Bioprecursor Prodrugs," in: <i>The Practice of Medicinal Chemistry</i> , Academic Press Limited 1996, pp. 697-715	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	47	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P289	White et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents." J. Med. Chem. 1996, 39, pp. 4382-4395	
	P289a	Wierzbowska et al., "Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia," Eur. Cytokine Netw., 14(3): 149-153 (Sept. 2003)	
	P289b	Wilhelm et al., "A Novel RAF Kinase Inhibitor Blocks the RAF/MEK/ERK Pathway in Tumor Cells," Poster, 92nd Annual Meeting of the American Association for Cancer Research, March 24-28, 2001, New Orleans, LA USA, 1 page	
	P290	Wilhelm et al., "BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis," Cancer Research, October 1, 2004, Vol. 64, pp. 7099-7109	
	P291	Wilhelm et al., "BAY 43-9006: Preclinical Data," Curr Pharm Des., 2002, Vol. 8, Number 25, pp. 2255-2257	
	P291a	Wilhelm et al., "Discovery and development of sorafenib: a multikinase inhibitor for treating cancer," Nature Reviews, Drug Discovery, 2006, Vol. 5, pp. 835-844	
	P291b	Wilhelm et al., "Preclinical overview of sorafenib: a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling," Mol. Cancer Ther., 2008, Vol. 7, No. 10, pp. 3129-3140	
	P293	Wilkinson Geoffrey, "Contents," 7 pages in: Comprehensive Organometallic Chemistry. The Synthesis, Reactions, and Structures of Organometallic Compounds, Pergamon Press, Oxford, U.K. 1982: Vol. 1-3	
	P294	Wilson et al., "The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase," Chemistry & Biology, 1997, Vol. 4, Number 6, pp. 423-431.	
	P294a	Stollorz, "Die Krebsformel, die der Zufall fand," Frankfurter Allgemeine Sonntagszeitung, July 2, 2006, NR 26, pp. 68-69	
	P295	Wissner et al., "Analogues of Platelet Activating Factor. 7. Bis-Aryl Amide and Bis-Aryl Urea Receptor Antagonists of PAF," J. Med. Chem., 1992, Vol. 35, pp. 4779-4789	
	P296	Wojnowski et al., "Endothelial apoptosis in Braf-deficient mice," Nature Genetics Vol. 16, pp. 293-297 (July 1997)	
	P297	Onyx Pharmaceuticals, Inc., "Novel RAF Kinase Inhibitor Bay 43-9006 Shows Early Signs of Tolerability and Activity in Phase IB Combination Trials Reported at ASCO," 1 page. (Press Release: June 2, 2003)	
	P298	Wright et al., "Bovine Immunodeficiency Virus Expression <i>in Vitro</i> is Reduced in the Presence of β -Chemokines, MIP-1 α , MIP-1 β and RANTES." Veterinary Research Communications. 2002: Vol. 26, pp. 239-250.	
	P299	Wright et al., "Clinical Trials Referral Resource. Current Clinical Trials of BAY 43-9006, Part 1," Oncology, April 2005, Vol. 19, No. 4: pp. 499-502	
	P299a	Wu et al., "Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment," International Journal of Oncology. 20: 509-516 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	48	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	^{1,6}
	P300	Xu et al., "Hypoxia-induced Elevation in Interleukin-8 Expression by Human Ovarian Carcinoma Cells," Cancer Research, 1999, Vol. 59, pp. 5822-5829	
	P301	He et al., "Oral Formulation of a Novel Antiviral Agent, PG301029, in a Mixture of Gelucire 44/14 and DMA (2:1, wt/wt)," AAPS PharmSciTech 2005; Vol.6 (1) Article 1, 5 pages, (http://www.aapsharmscitech.org)	
	P301a	Yamaguchi et al., "Expression of Vascular Endothelial Growth Factor in Human Hepatocellular Carcinoma," Hepatology, 28(1) pp. 68-77 (1998)	
	P302	Yang et al., "Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of a Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt," Cancer Research, 64, July 1, 2004, pp. 4394-4399	
	P303	Yang et al., "Antiviral chemotherapy control of poxvirus infections through inhibition of cellular signal transduction," The Journal of Clinical Investigation, 2005: 115(2):pp. 379-387	
	P304	Yeh et al., "Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution," Proc. Natl. Acad. Sci. USA 2004-02-24, 101(8):2542-2547	
	P305	Yu et al., "The role of Mel-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006," Oncogene 24:6861-6869 (2005)	
	P306	Zachos et al., "Herpes Simplex Virus Type 1 Infection Stimulates p38/c-Jun N-terminal Mitogen-activated Protein Kinase Pathways and activates Transcription Factor AP-1," Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc. 1999: Vol. 274, pp. 5097-5103	
	P306a	Zangari et al., "Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma," Clinical Cancer Research, 10: 88-95 (Jan 1, 2004)	
	P307	Norden-Zfoni, Anat. "Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor," Clin. Cancer. Res. 2007: 13(9):2643-2650 May 1, 2007	
	P308	Zhao et al., "Moderate mutation rate in the SARS coronavirus genome and its implications," BMC Evolutionary Biology, 2004, 4:21, 9 pages	
	P309	Zhu et al., "From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3- Phosphoinositide-Dependent Protein Kinase-1 Inhibitors," Cancer Research 64, June 15, 2004, pp. 4309-4318	
	P310	Carter et al., "Anti-tumor Efficacy of the Orally Active RAF Kinase Inhibitor Bay 43-90006 in Human Tumor Xenograft Model," #4954. Proceedings of the American Association for Cancer Res., 2001, Vol. 42, p. 923	
	P311	Iwadate et al., MEDLINE/NLM, NLM8336809 "Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion," 1 page, abstract	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	49	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1 ⁶
	P312	Kubo et al., "Synthesis and Structure-Activity Relationship of Quinazoline-Urea Derivatives as Novel Orally Active VEGF Receptor Tyrosine Kinase Selective Inhibitors," Proceedings of the American Association of Cancer Res., 2002, Vol. 43, p. 182, abstract no. 913	
	P313	Riedl et al. # 4956 "Potent Raf Kinase Inhibitors from the Diphenylurea Class: Structure Activity Relationships," Proceedings of the American Association for Cancer Research, Vol. 42, March 2001 (2001-03), page 923, 92nd Annual Meeting of the American Association for Cancer Research; New Orleans, LA, USA; March 24-28, 2001	
	P314	Strumberg et al., abstract no. #2921 "Phase 1 and Pharmacokinetic Study of the Raf Kinase Inhibitor Bay 43-9006 in Patients with Locally Advanced or Metastatic Cancer," Proceedings of the American Association for Cancer Research, vol. 42, March 2001 (2001-03), page 543, 92nd Annual Meeting of the American Association for Cancer Research; New Orleans, LA, USA; March 24-28, 2001	
	P315	Abstract of DE 3305866 A1, August 23, 1984, BASF AG et al.	
	P316	Abstract of EP 4931 A (Equivalent 4,240,820), Bayer AG, 1 page	
	P317	Abstract of EP 16371 (1980), 1 page, Hoffmann-La Roche AG	
	P318	Abstract of EP 16371, October 1, 1980, 1 page	
	P319	Abstract of EP 116932, August 29, 1984, 2 pages.	
	P320	Abstract of EP 116932, (1984), 2 pages, BASF AG	
	P321	Abstract of EP 0202538, (1986), 3 pages	
	P322	Abstract of EP 0202538 A1, "Growth Promoting Agents, November 26, 1986, 4 pages, Bayer AG	
	P323	Abstract of EP 0405233A1, Mitsubishi Kasei Corp., 2 pages	
	P324	Abstract of EP 0405233A1, Tetsuo Sekiya et al., 1 page	
	P325	Abstract of EP 0676395A2, (1995), 3 pages, Hoechst AG	
	P326	Abstract of EP 676395, (U.S. equivalent 5,698,581), December 16, 1997, 1 page	
	P327	Patent Abstracts of Japan 02-022650, 01-25-1990, 2 pages, Konica Corp.	
	P328	esp@cenet Abstracts of Japan 02-022650, 01-25-1990, 1 page	
	P329	Patent Abstracts of Japan 02-023337, 01-25-1990, 2 pages, Konica Corp.	
	P329a	Patent Abstracts of Japan 63-214752, 09-07-1988, 2 pages, family member of JP 6-07512 B4, Fuji Photo Film Co. Ltd.	
	P330	esp@cenet Abstract of Japan 02-023337, 1 page	
	P331	Abstract of JP 55162772 A2, Preparation of Substituted Acetic Acid Derivatives, Shiongi & Co., Ltd. December 1980, 1 page	
	P332	Esp@cenet Abstract of WO 9822103, 28 May 1998, Philip Hedge et al.	
	P332a	Abstract of WO 9822098 A2, QLT Phototherapeutics Inc. et al., 05-28-1998, 1 page	
	P333a	Abstract of WO 9822103 A1, Zeneca Limited, published 05-28-1998, 1 page	
	P333b	Abstract of WO 9852559 A1, Bayer Corp. et al., published 11-26-1998, 1 page	
	P333c	Abstract of WO 9852562 A1, Verkaik, MSE, et al., published 11-26-1998, 1 page	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	50	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P333d	Abstract of WO 9900357 A1, Vertex Pharm. Inc., published 01-07-1999, 1 page	
	P333e	Abstract of WO 9900364 A1, Pharmacia & Upjohn S.P.A. et al., published 01-07-1999, 1 page	
	P333f	Abstract of WO 9932098 A2, Janssen Pharm NV, published 07-01-1999, 1 page	
	P333g	Abstract of WO 9932106 A1, Bayer Corp., published 07-01-1999, 1 page	
	P333h	Abstract of WO 9932148 A1, Beth Israel Deaconess Medical Center et al., pub. 07-01-1999, 1 page	
	P333i	Abstract of WO 9932436 A1, Bayer Corp., published 07-01-1999, 1 page	
	P333j	Abstract of WO 9932455 A1, Bayer Corp., published 07-01-1999, 1 page	
	P333k	Abstract of WO 9932457 A1, Hoechst Marion Roussel Deutschland GmbH et al., published 07-01-1999, 1 page	
	P334	Caplus 72:79046, Abstract of CH 479557, "Tuberculostatic and cancerostatic polybasic ureas," Dr. A. Wander, October 15, 1969, 6 pages	
	P335	Caplus 84:180049, Abstract JP 56029871, "Substituted acetic acid derivatives," Hamada, Yoshinori et al., July 10, 1981, 1 page	
	P336	Caplus 84:43857, Abstract JP 58021626, "Alkanoic acid derivatives containing a pyridine ring," Maeda, Ryoza et al., May 2, 1983, 1 page	
	P337	Caplus 86:72448, Abstract JP 57053785, "Pyridine derivatives," Maeda, Ryoza et al., November 15, 1982, 1 page	
	P338	Caplus 87:62295, "The metabolism and toxicity of halogenated carbanilides. Biliary metabolites of 3,4,4'-trichlorocarbanilide and 3-trifluoromethyl-4,4'-dichlorocarbanilide in the rat," Chemical Life Science, pp. 157-66, 1977, 1 page	
	P339	Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives," November 15, 1982, 1 page, Chugai Pharmaceutical Co., Ltd.	
	P340	Caplus 113:106314, Abstract of JP 2022650, "Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove leuco cyan dye," Noboru Mizukura et al. January 25, 1990, 1 page	
	P341	Caplus 113:142130, Abstract of JP 2023337, "Silver halide photographic material containing phenolic cyan coupler a colorless cyan coupler," Toshihiko Yagi et al., January 25, 1990, 1 page	
	P342	Caplus 125:245169, "Production of murine monoclonal antibodies against sulcofuron and flucufuron by in vitro immunization," G. A. Bonwick et al., J. Immunol. Methods, 196(2), pp. 163-173, 1996, 1 page	
	P343	Caplus 126:166148, "Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells," James D. Winkler et al., J. Pharmacol. Exp. Ther. 279(2), pp. 956-966, 1996, 2 pages	
	P344	Dearden et al., "Quantitative structure-biodegradability studies: an investigation of the MITI aromatic compound data-base," in: Biodegradability Prediction, Edited by Willie J.G.M. Peijnenburg et al., NATO ASI Series, 2. Environment - Vol. 23, pp. 93-104, 1996	
	P345	Caplus 127:293717, "Optical properties of segmented oligourethane with azomethine terminal fragments," National Academy of Science of Ukraine, M. V. Kurik et al., pp. 2038-2041, 1996, 2 pages	
	P346	Caplus 127:34137f, "Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation," Kazuo Kubo et al., May 15, 1997, WO 97/17329	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	51	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹⁶
	P347	Caplus 131:58658k, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas," Miller, Scott, et al. July 1, 1999, WO 99 32,436	
	P348	Caplus 131:73649b, "Preparation of pyrazolyl aryl ureas and related compounds as p38 kinase inhibitors," Jacques Dumas et al., July 1, 1999, WO 99/32110	
	P349	Caplus 131:87909y, "Inhibition of p38 kinase activity using substituted heterocyclic ureas," Jacques Dumas et al., July 1, 1999, WO 99/32111	
	P349a	Caplus 146:265643 Abstract of Strumberg et al., "Sorafenib - A novel opportunity in oncology," Arzneimitteltherapie 25(1):2-6 (2007) abstract, 1 page	
	P350	Kujundzic et al., "Synthesis of 8-methyl-1,2,3,4-tetrahydropyrido[3,4-d] pyrimidine-2,4-diones," Croat. Chem. Acta (1991) 64(4):599-606, Chemical Abstracts Vol. 116, No. 21, 25 May 1992, (pp. 741-742) No. 116:214456	
	P351	Badran et al., "Novel piperazinyl-substituted pyrimidines as antihypertensive and vasodilators," Revue Roumaine de Chimie (1992), 37(2):238-288, Chemical Abstracts Vol. 117:251318	
	P352	"Beilstein number" Collection, 28 pp. (1997)	
	P353	"Beilstein number" Collection, 4 pp. (1997)	
	P354	Derwent World Patents Index Search, pp. 20-26. (1997)	
	P355	Dumas, J. "CAS Substructure," May 6, 1997, pp. 1-29	
	P356	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pp. 1-19	
	P357	Scott, Bill, "Substructure #2," November 25, 1997, pp. 1-3	
	P358	Scott, Bill, "Substructure Search," December 2, 1997, pp. 1-49	
	P359	Substructure Search, pp. 1-29. (1997)	
	P360	Wild, Hanno, "Substructure #1," search, pp. 1-150, 1996	
	P361	A "Notice of References Cited" from the USPTO for U.S. application 08/995,749, filing date of 12/22/97, Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas, 2 pages	
	P362	A "Notice of References Cited" from the USPTO for U.S. application 09/083,399, filing date of 5/22/98, Patent 6187799 issued 2/13/2001, Inhibition of Raf Kinase Activity Using Aryl Ureas, 1 page	
	P363	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228, filing date of 10/22/99, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 3 pages	
	P364	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229, filing date of 10/22/99, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, 1 page	
	P365	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015, filing date of 12/10/1999, Inhibition Of p38 Kinase Using Symmetrical And Unsymmetrical Diphenyl Ureas, 1 page	
	P366	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Patent 7329670 issued 2/12/2008, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	52	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	P367	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Patent 7329670 issued 2/12/2008, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P368	A "Notice of References Cited" from the USPTO for U.S. application 09/773,604, filing date of 2/2/01, Publication No. US 2001-0034447-A1, Publication Date 10/25/01, Omega-carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	
	P369	A "Notice of References Cited" from the USPTO for U.S. application 09/773,659, filing date of 2/2/01, Publication No.: US 2001-0011135 A1, Publication Date: August 2, 2001, Omega-carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page	
	P370	A "Notice of References Cited" from the USPTO for U.S. application 09/773,672, filing date of 2/2/01, Publication No.: US 2001-0016659 A1, Publication Date: August 23, 2001, Omega-carboxyaryl substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	
	P371	A "Notice of References Cited" from the USPTO for U.S. application 09/773,675, filing date of 2/2/01, Publication No.: US 2001-0011136-A1, Publication Date: August 2, 2001, Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	
	P372	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935 filing date of 12/22/98, Inhibition Of p38 Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P373	A "Notice of References Cited" from the USPTO for U.S. application 09/776,936, filing date of 12/22/98, Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, 1 page	
	P374	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920, filing date of 2/7/01, Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas, 1 page	
	P375	A "Notice of References Cited" from the USPTO for U.S. application 09/948,915, filing date of 9/10/01, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page	
	P376	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226, filing date of 01/11/2002, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page	
	P376a	Co-pending application Serial No. 09/458,014, filed December 10, 1999, Dumas et al.	
	P377	Abandoned application Serial No. 09/776,935 filed December 22, 1998, Dumas et al.	
	P378	Co-pending application Serial No. 09/776,936 filed December 22, 1998, Miller et al.	
	P379	Issued application Serial No. 09/889,227 filed July 12, 2000, Riedl et al., issued as 7351834, 4/1/2008	
	P380	Co-pending application Serial No. 09/993,647 filed November 27, 2001, Riedl et al., published as 2003-0181442, 9/25/2003	
	P381	Issued application Serial No. 10/060,396 filed February 1, 2002, Miller et al., patent 7517880, issued 4/14/2009, also published as 2004-0102636, 5/27/2004	
	P382	Issued application Serial No. 10/071,248 filed February 11, 2002, Riedl et al., patent 7528255, issued 5/5/2009, also published as 2003-139605, 7/24/2003	
	P383	Abandoned application Serial No. 10/086,417 filed March 4, 2002, Riedl et al., published as 2003-0105091, 6/5/2003	
	P384	Abandoned application Serial No. 10/125,369 filed April 19, 2002, Dumas et al., published as 2003-0207914, 11/6/2003	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	53	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P385	Abandoned application Serial No. 10/308,187 filed December 3, 2002, Carter et al., published as 2003-0232765, 12/18/2003	
	P386	Abandoned application Serial No. 10/361,844 filed February 11, 2003, Dumas et al., published as 2004-0023961, 2/5/2004	
	P387	Abandoned application Serial No. 10/361,850 filed February 11, 2003, Dumas et al., published as US 2003-0216396, 11/20/2003	
	P388	Co-pending application Serial No. 10/361,859 filed February 11, 2003, Dumas et al., published as 2003-0216446, 11/20/2003	
	P389	Co-Pending U.S. Patent Application No. 10/895,985 filed July 22, 2004, Boyer et al., published as US 2005-0038080, 2/17/2005	
	P389b	Co-Pending U.S. Patent Application No. 11/932,548 filed October 31, 2007, Dumas et al.,	
	P390	Co-Pending U.S. Patent Application No. 12/084,662 filed May 7, 2008, Sandner et al., published as 2010-0035888, 2/11/2010.	
	P391	Co-Pending U.S. Patent Application No. 12/086,454 filed June 12, 2008, Weber et al.	
	P391a	Co-Pending U.S. Patent Application No. 12/093,515 filed November 13, 2008, Wilhelm et al.	
	P392	Co-Pending U.S. Patent Application No. 12/095,611 filed May 30, 2008, Smith et al.	
	P393	Co-Pending U.S. Patent Application No. 12/158,524 filed June 20, 2008, Smith et al.	
	P394	Co-Pending U.S. Patent Application No. 12/294,979 filed September 29, 2008, Wilhelm et al.	
	P394a	Co-Pending U.S. Patent Application No. 12/421,690 filed April 10, 2009, Dumas et al.,	
	P395	Co-Pending U.S. Patent Application No. 12/444,974 filed April 9, 2009, Grunenberg et al.	
	P396	Co-Pending U.S. Patent Application No. 12/514,129 filed May 8, 2009, Grunenberg et al.	
	P397	Co-Pending U.S. Patent Application No. 12/514,715 filed May 13, 2009, Stiehl et al.	
	P398	Co-Pending U.S. Patent Application No. 12/520,618 filed June 22, 2009, Smith et al.	
	P399	Co-Pending U.S. Patent Application No. 12/520,609 filed June 22, 2009, Smith et al.	
	P400	Co-pending U.S. Patent Application No. 12/523,652 filed July 17, 2009, Wilhelm et al.	
	P401	Co-pending U.S. Patent Application No. 12/523,697 filed July 17, 2009, Wilhelm et al.	
	P402	Co-Pending U.S. Patent Application No. 12/628,735 filed December 1, 2009, Dumas et al.	
	P402a	Co-Pending U.S. Patent Application No. 12/692,845 filed January 25, 2010, Dumas et al.	
	P403	Co-Pending Application PCT/US09/61506, filed October 21, 2009, Carol Pena	
	P404	International search report for International Application No. PCT/US98/10375 dated 9/3/98, Inhibition Of p38 Kinase Activity By Aryl Ureas, publication No. 98/52558, publication date 11/26/1998, 1 page	
	P405	International search report for International Application No. PCT/US98/10376 dated 7/30/98, Raf Kinase Inhibitors, publication No. WO 98/52559, publication date 11/26/1998, 1 page	
	P406	International search report for International Application No. PCT/US98/26078 dated 4/2/99, Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas, publication no. WO 99/32106, publication date 7/1/1999, 2 pages	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	54	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P407	International search report for International Application No. PCT/US98/26079 dated 4/12/99, Inhibition Of p38 Kinase Activity Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 99/32110, publication date 7/1/1999, 1 page	
	P408	International search report for International Application No. PCT/US98/26080 dated 4/12/99, Inhibition Of p38 Kinase Using Substituted Heterocyclic Ureas, publication No. WO 99/32111, publication date 7/1/1999, 1 page	
	P409	International search report for International Application No. PCT/US98/26081 dated 4/2/99, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS, publication No. WO 99/32436, publication date 7/1/1999, 1 page	
	P410	International search report for International Application No. PCT/US98/26082 dated 5/12/99, Inhibition Of Raf Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 99/32455, publication date 7/1/1999, 1 page	
	P411	International search report for International Application No. PCT/US98/27265, dated 3/2/99, Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas, publication No. WO 99/32463, publication date 7/1/99, 1 page	
	P412	International search report for International Application No. PCT/US00/00648 dated 6/29/00, Omega-Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase Inhibitors, publication No. WO 00/42012 A1, publication date 7/20/2000, 2 pages	
	P413	International search report for International Application No. PCT/US00/00768 dated 5/16/00, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication No. WO 00/41698 A1, publication date 7/20/2000, 1 page	
	P414	International search report for International Application No. PCT/US02/12064 dated 9/20/02, HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS, publication No. 02/085859, publication date 10/31/2002, 2 pages	
	P415	International search report for International Application No. PCT/US02/12066 dated 9/27/02, Inhibition Of Raf Kinase Quinolyl, Isoquinolyl Or Pyridyl Ureas, publication No. 02/085857, publication date 10/31/2002, 2 pages	
	P416	Supplemental search report from the EPO for European application EP 98963809.3 dated 3/30/01, Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, publication No. 1049664, publication date 7/1/1999, granted 3/16/2005, 4 pages	
	P417	Supplemental search report from the EPO for European application EP 98963810.I dated 12/21/00, Inhibition Of Raf Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. 1056725, publication date 7/1/1999, granted 6/7/2006, 4 pages	
	P418	Supplemental search report from the EPO for European application EP 98965981.8 dated 12/21/00, Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas, publication No. 1047418, publication date 7/1/1999, granted 7/27/2005, 8 pages	
	P419	Supplemental search report from the EPO for European application EP 00903239.2 dated 8/7/02, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, publication no. EP 1140840, published 7/20/2000, granted 3/22/2006, 6 pages	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	55	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	⁶
	P420	Supplemental search report from the EPO for European application EP 00905597.1 dated 2/7/08, Omega-Carboxyaryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication no. EP 1158985, 7/20/2000, 9 pages	
	P421	Belgore et al., "Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays," Clinical Science, 100: 567-575 (2001)	
	P422	Belgore et al., "Plasma Levels of Vascular Endothelial Growth Factor (VEGF) and Its Receptor, Flt-1, in Haematological Cancers: A Comparison With Breast Cancer," American Journal of Hematology, 66:59-61 (2001)	
	P423	Coskun et al., "Significance of serum vascular endothelial growth factor, insulin-like growth factor-1 levels and nitric oxide activity in breast cancer patients," The Breast, 12, 104-110 (2003)	
	P424	Kaya et al., "The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients," Respiratory Medicine, 98:632-636 (2004)	
	P425	Kumar et al., "Soluble FLT-1 is Detectable in the Sera of Colorectal and Breast Cancer Patients," Anticancer Research, 22:1877-1880 (2002)	
	P426	Pasieka et al., "Evaluation of the Levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in Serum of Patients with Thyroid Cancer," Recent Results in Cancer Research, 162:189-194 (2003)	
	P427	Pegram et al., "Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/neu Protein and Vascular Endothelial Growth Factor," Seminars in Oncology, 29(Suppl. 11):29-37 (2002)	
	P428	Poon et al., "Prognostic significance of serum vascular endothelial growth factor an endostatin in patients with hepatocellular carcinoma," British Journal of Surgery, 91:1354-1360 (2004)	
	P429	Ria et al., "Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy," Cancer Letters, 216:103-107 (2004)	
	P430	Secord et al., "The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer," Gynecologic Oncology, 94:74-79 (2004)	
	P431	English abstract of JP 10-306078, 1998-11-17, Patent Abstracts of Japan, 2 pages	
	P432	English abstract of JP 08-301841, 1996-11-19, Patent Abstracts of Japan, 2 pages	
	P433	English abstract of JP 03-198049, 1991-08-29, Patent Abstracts of Japan, 1 page	
	P434	English abstract of JP 03-144634, 1991-06-20, Patent Abstracts of Japan, 1 page	
	P435	English abstract of JP 03-053247, 1991-03-07, Patent Abstracts of Japan, 1 page	
	P436	English abstract of JP 02-150840, 1990-06-11, Patent Abstracts of Japan, 1 page	
	P437	English abstract of JP 02-108048, 1990-04-19, Patent Abstracts of Japan, 1 page	
	P438	English abstract of JP 02-105146, 1990-04-17, Patent Abstracts of Japan, 1 page	
	P439	English abstract of JP 02-035450, 1990-02-06, Patent Abstracts of Japan, 1 page	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/993,647
				Filing Date	November 27, 2001
				First Named Inventor	Bernd Riedl et al.
				Group Art Unit	1624
				Examiner Name	Deepak R. RAO
Sheet	56	of	56	Attorney Docket Number	BAYER-0018-A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ⁶	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹⁻⁶
	P440	English abstract of JP 01-200254, 1989-08-11, Patent Abstracts of Japan, 1 page	
	P441	English abstract of JP 01-259360, 1989-10-17, Patent Abstracts of Japan, 2 pages	
	P442	English abstract of JP 01-102461, 1989-04-20, Patent Abstracts of Japan, 1 page	
	P443	English abstract of JP 06-120039, 1994-04-28, Patent Abstracts of Japan, 1 page	
	P444	English abstract of JP 05-180862, 1993-07-23, Patent Abstracts of Japan, 1 page	
	P445	English abstract of JP 05-163170, 1993-06-29, Patent Abstracts of Japan, 1 page	
	P446	English abstract of JP 05-077375, 1993-03-30, Patent Abstracts of Japan, 1 page	
	P447	English abstract of JP 05-076072, 1993-03-26, Patent Abstracts of Japan, 2 pages	
	P448	English abstract of JP 50-149668 A and JP 56-29871 B, Derwent World Patents Index, Dialog File No. 351, Acc. No. 1488399, 3 pages	
	P449	English abstract of JP 53-086033, 1978-07-29, Patent Abstracts of Japan, 1 page	
	P450	English abstract of JP 54-032468, 1979-03-09, Patent Abstracts of Japan, 1 page	
	P451	English abstract of JP 55-098152, 1980-07-25, Patent Abstracts of Japan, 1 page	
	P452	English abstract of JP 64-009455, 1989-01-12, Patent Abstracts of Japan, 1 page	
	P453	English abstract of JP 02-023337, 1979-03-09, Patent Abstracts of Japan, 2 pages	
	P454	English abstract of EPA 0379915/EP-A1, 1990-08-01, 2 pages	
	P455	English abstract of DD 253997 A, 1988-02-10, 1 page	
	P456	English abstract of DE511468, European Patent Office, 2 pages	
	P457	Co-Pending U.S. Patent Application No. 12/619,913, filed November 17, 2009, Ranges et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.